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ABSTRACT 
  
Background: Parenteral nutrition (PN) is a treatment provided to very low birth weight neonates 
during their hospital stay. PN is comprised of the essential nutrients, minerals, fluids, and 
electrolytes required for sustenance. If healthcare personnel follow the current published infant 
PN guidelines of an internationally recognized nutritional organization (e.g., American Society 
for Parenteral and Enteral Nutrition), they can improve the efficacy of their PN treatment. While 
a host of PN practices in developed countries have been described in scientific literature, there is 
a lack of knowledge about the PN practices in developing countries (Katoue, Al-Taweel, Matar, 
& Kombian, 2016). This lack of evidence also applies to the PN practices employed in Ecuador.  
Ecuadorian PN practices have not been well studied and, therefore, relevant literature is 
unavailable.  
Objectives: Describe the current PN practices and resources in public hospital neonatal wards 
(n=4) in Quito, Ecuador. Furthermore, identify whether current PN practices are standardised and 
examine the prevalence of the most common side effects associated with PN.  
Design:  Survey of health professionals delivering PN treatment at four neonatal intensive care 
unit (NICU)s. Furthermore, a retrospective chart review of neonates who received PN treatment 
from June 2016 to June 2017.   
Setting:  Four public neonatal wards in Quito, Ecuador  
Results:  Our study showed that thirteen out of sixteen interviewees follow PN protocols or 
consensus developed by their units or by the Ecuadorian Ministry of Health or published 
guidelines. Furthermore, all of the NICUs developed an Excel conversion spreadsheet to help 
professionals automate the ordering PN solutions to avoid potential errors during the prescription 
of this treatment. Other findings noted that the lack of a formal and functional nutritional support 
team was common in the observed NICUs and that there is little participation from dietitians in 
PN treatment. Finally, our study found that during week one to week four of PN treatment, the 
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mean levels of amino acids, lipids, energy intake, the glucose infusion rates, and conjugated 
bilirubin differed significantly between Hospital Gineco-Obstetrico Isidro Ayora’s and Hospital  
Gineco-Obstetrico Nueva Aurora’s NICUs.  
Conclusions: The participants at the public NICUs in Quito endeavoured to meet the 
recommendations of published guidelines, despite the observed challenges and limitations. Our 
study found that there are opportunities for safety and quality improvement. Awareness of these 
opportunities will allow NICUs to fill gaps in their procedures to ensure better practices and, 
therefore, safer PN treatment.  
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1. INTRODUCTION 
1.1 Rationale  
Parenteral nutrition (PN) is one of the treatments provided to very low birth weight 
(VLBW) and extremely low birth weight (ELBW) neonates, defined as an infant born under 28 
days of age weighing less than 1500g and 1000g respectively (World Health Organization, 2003). 
During their hospital stay, many infants will require PN for approximately three weeks. (Porcelli, 
2004). PN is comprised of nutrients including d-glucose, vitamins, dietary minerals, lipids, and 
amino acids (Mirtallo et al., 2004). When no significant nutrition can be provided to the neonate 
by enteral routes, such as breastfeeding, PN is administered. PN is called total parenteral nutrition 
(TPN) and partial parenteral nutrition (PPN) when it is a total or partial component of a neonates 
diet respectively (Mirtallo et al., 2004). In this study, the word PN is used to describe the collective 
practices and resources used in public hospitals in Quito, Ecuador.   
The dose of specific nutrients in the PN formulation is administered within accepted age-
based standards but can vary according to clinical situations. If healthcare personnel follow the 
published clinical guidelines of an internationally recognized nutritional organization (e.g., 
American Society for Parenteral and Enteral Nutrition) for the safe prescription and administration 
of PN, the risk of complications is reduced, and the health outcomes of these vulnerable infants 
are improved (Duggan et al., 2002).   Although PN practices in developed countries are well 
described in the existing literature, this is not the case for the procedures and policies used in 
developing countries (Katoue, Al-Taweel, Matar, & Kombian, 2016). This limitation affects 
neonatal PN use in public neonatal intensive care units (NICUs) in Quito where practices have 
not previously been described in scientific literature.  
This study will describe the current PN practices, resource availability, and complications 
associated with PN practices in four public hospital NICUs in Quito, Ecuador. The methodology 
consists of a face-to-face closed-ended and open-ended questionnaire of 58 questions. Three to 
five healthcare personnel from each neonatal unit who are responsible for delivering PN treatment 
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to infants were queried. Through the survey, we will be able to obtain a clear snapshot of current 
PN practices, resources, challenges faced and lessons learned, and gain a clearer understanding of 
how PN practices and outcomes compare to those in other developed and developing countries.  
As well, a retrospective medical record review of neonates who received PN will be conducted 
which will capture practices and outcomes from June 2016 to June 2017. We will have access to 
approximately one hundred neonate medical records from each hospital. These records will also 
be used to determine any complications associated with PN. Additionally, the medical records 
will provide direct bilirubin, blood glucose levels, and blood and catheter microbial culture 
information.   
1.2 Objectives of this study:  
1. describe the current PN practices and resources  
2. identify if current PN practices are standardized   
3. examine the prevalence of the most common complications associated with PN in patients 
who received PN  
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2. LITERATURE REVIEW 
2.1 Parenteral nutrition as a nutritional treatment for neonate patients  
  Humans have struggled with providing medical care for neonates and premature babies, 
including determining their feeding requirements and the best types of nutritional treatments, 
since the origin of nutritional support care. In the 17th century, for example, physicians suggested 
using opium, wine, and oil (Grant, 1980).  Modern PN was first introduced to provide nutritional 
support to postoperative neonates in 1969 (Burjonrappa & Miller, 2012). Prior to this, PN was 
administered to adult patients with gastrointestinal tract issues that hindered their uptake of 
adequate nutrition (Grant, 1980). This nutritional treatment was then extended to very low birth 
rate (VLBW) and premature infants, along with those suffering from protracted diarrhea and those 
who had undergone major gastrointestinal surgery (British Association of Perinatal Medicine, 
2016; Chaudhari & Kadam, 2006). At the onset of its use, PN was provided to VLBW and ELBW 
neonates.  
 Presently, PN is used to promote the physical, psychomotor and neurodevelopmental 
growth of neonates (British Association of Perinatal Medicine, 2016). In his cohort study, 
Stephens (2009) aimed to determine the association between early protein and energy intake and 
growth and neurodevelopment in 124 ELBW infants who received parenteral and enteral nutrition 
during their first four weeks of life. This study found that there was an association between higher 
protein intake with lower probability of length <10th percentile at the 18-month follow-up visit. 
Furthermore, it showed that for every 10 kcal/kg/day of energy intake and a protein intake of 
1g/kg/day were independently associated with 4.6 and 8 points increase in the Bayley Mental 
Development Index second edition (MDI-II) (MDI mean 79± 16, MDI <70 29%) respectively at 
the 18-month follow-up visit (Stephens et al., 2009). The MDI-II is an integrative developmental 
assessment which measures language development and early cognitive function in young children 
(Lowe, Erickson, Schrader & Duncan, 2012).   
In addition to the Stephens’ study findings, a similar randomized clinical trial was 
designed to determine if the early provision of amino acids was associated with better growth and 
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neurodevelopmental outcomes in patients. At the 18-month follow-up visit, the early intervention 
group of male neonates who received ≥3g/kg/day of parenteral amino acids and high energy intake 
during the first five days of life had a reduced probability of having a head circumference under 
the fifth  percentile compared to the late intervention group of neonates who did not receive the 
minimum of 3g/kg on any single day during the first five days of life. Despite this finding, the 
study did not find any significant differences between early and late groups in terms of weight, 
length, and MDI-II scores (MDI mean 78.1 ± 16, MDI<70 33% and MDI mean 79 ±18.2, MDI 
<70 32% respectively) (Poindexter, Langer, Dusick, & Ehrenkranz, 2006).   
As it has been shown in the aforementioned studies, the early provision of parenteral amino 
acid and energy intake to neonate patients promotes positive outcomes in the infant’s length and 
head circumference. Even though Poindexter’s study found no statistical difference between the 
early and late groups relating to their neurodevelopmental outcomes, the MDI mean and MID <70 
scores obtained by both groups in this study were quite similar to the scores obtained by the 
neonates in Stephen’s study. This similarity suggests that the neonates in both studies experienced 
a positive impact on their neurodevelopment due to the early provision of the amino acids through 
the PN treatment.  
2.2 PN Clinical guidelines  
Currently, PN treatment is considered by the Institute for Safe Medication Practices to be 
a high-risk medication (Institute for Safe Medication Practices, 2017). Due to the potential risks, 
especially the risk of PN formulation contamination, it is important to develop and implement 
policies, procedures, and practices that are science and evidence-based (Boullata, 2012). Specific 
protocols and guidelines can and should be developed as these guidelines may reduce the potential 
complications associated with PN treatment (Mirtallo et al., 2004). Guidelines suggest that a 
standardized ordering step should be developed following protocols and that a regular audit should 
be periodically performed (Mirtallo et al., 2004; British Association of Perinatal Medicine, 2016; 
Embleton & Simmer, 2014).  
  Hudson and Boullata (2014) argued that both standardizing each step of PN treatment, 
including prescribing, reviewing, formulating, administrating, monitoring and weaning the 
neonate, and improving communication are important strategies to minimize the risk of possible 
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complications associated with PN administration. Thus, over the ten years period of their quality 
improvement study, they identified fifteen opportunities for improvement in all the PN processes.  
At the baseline of the study, thirteen gaps were identified and corrected to meet the American 
Society for Parenteral and Enteral Nutrition (ASPEN) guidelines’ recommendations (Hudson & 
Boullata, 2014). One clear example of this intervention was noted in the reviewing step when a 
previous recommendation described that a pharmacist should “review or verify each PN order,” 
while the optimum criteria proposed that guidelines “identify the individual who reviews/verifies 
each PN” order (Hudson & Boullata, 2014, p. 383).  
  In addition to the standardization of the PN process, the British Association of Perinatal 
Medicine (2016) and Mirtallo (2004) suggest that only trained healthcare professionals should be 
allowed to prescribe PN, perform compounding, and administer PN to avoid dangerous mistakes. 
In fact, a multidisciplinary team comprised of physicians, dietitians, pharmacists, and nurses must 
be responsible for delivering PN treatment according to these guidelines (British Association of 
Perinatal Medicine, 2016; Mirtallo et al., 2004).  
Among clinical guidelines, there are discrepancies related to the recommended indications 
for initiating and stopping PN in neonate patients. Some of these guidelines indicate that PN 
should be initiated primarily in neonates below 30 or 32 weeks of gestational age, infants below 
1250g or 1500g of body weight, and infants suffering from a failure of successful enteral nutrition 
(British Association of Perinatal Medicine, 2016; Embleton & Simmer, 2014).  Other guidelines 
recommend that all neonates below 35 weeks of gestation should receive PN treatment (Fusch et 
al., 2009). The main goal of these recommendations is to reach the full enteral nutrition 
(150180ml/kg/day) in the shortest time (two to one weeks depending on the birth weight of the 
patient, <1000g or 1000-1500g respectively), assuring adequate growth and avoiding potential 
complications (Dutta et al., 2015).  
2.2.1 PN composition and daily requirements   
Newborns requiring PN should receive a glucose and amino acid formulation immediately 
after birth and lipids 24 hours after birth; postponed therapy given three days after birth greatly 
compromised the health of the neonates (British Association of Perinatal Medicine, 2016; 
Embleton, Pang, & Cooke, 2001). Neonates who receive protein support in the first day of life are 
known to have positive health outcomes in terms of a shorter hospital stay, positive nitrogen 
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balance, and earlier introduction of enteral nutrition. Additionally, receiving protein support on 
the first day of life can avert a negative nutrient balance (Trivedi, & Sinn, 2013; Schanler, 
Shulman, & Prestridge, 1994). Heimler, Bamberger, and Sasidharan (2010) in their randomized 
controlled trial in VLBW infants, which aimed to evaluate the effects of early parenteral amino 
acid on neonates’ weight, metabolic parameters, and fluid compartments, found that plasma urea 
levels were significantly higher in the early group, neonates who received 1.5 g/kg of amino acids 
within 24 hours of life compared to the late group, neonates who received 1g/kg of amino acid at 
78 hour of life. In addition, the early group presented a positive nitrogen balance and the late 
group a negative nitrogen balance. There were no statistical differences between the two groups 
in terms of weight and plasma ammonia levels (Heimler, Bamberger, & Sasidharan, 2010).   
Similar to Heimler et al.’s study, a previous randomized open trial in VLBW neonates 
received 2.4g/kg per day of parenteral amino acids within two hours of life also who had a positive 
nitrogen balance at postnatal day two while patients who did not receive this macronutrient within 
the two first days of life had a negative nitrogen balance (Van Den et al., 2006).  Another 
randomized control trial which supported the positive outcomes of early PN administration 
showed that the early administration of amino acids to randomized VLBW and low birth weight 
(LBW) neonate patients allowed them to regain birth weight earlier when compared to the control 
group (mean 11.7 (SD 4.6) days versus 14.1 (SD 4.1) respectively). Furthermore, the treated group 
had a shorter hospital stay and time to full feeds compared to the control group (mean 33.1 (SD 
13.9) days versus 40.3 (SD 15.7) and mean 13.9 (SD 4.3) versus 16.1 (SD 4.7) days respectively) 
(Trivedi, & Sinn, 2013).   
 To avoid essential fatty acid deficiency, the British Association of Perinatal Medicine 
(2016) recommends that a neonate must receive a 20 % lipid emulsion with in the first 24 hours 
of life. Parenteral iron is not recommended in the first three weeks of life (British Association of 
Perinatal Medicine, 2016). PN should include both fat-soluble and water-soluble vitamins. 
Supplementation with magnesium, phosphate, and trace elements should be included if the PN 
therapy is expected to exceed seven days (Fusch et al., 2009). Despite decades of PN use, there is 
still no consensus as to the concentration of nutrients and the daily dose provided to infants 
(British Association of Perinatal Medicine, 2016). Table 2.1 shows the range of specific 
ingredients and the daily PN dose recommendations from a variety of sources.  
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     Table 2.1 Varying range of ingredients and the daily PN dose recommendations.    
Nutrient  
  
Safe Practices for  
PN (ASPEN)  
(Mirtallo et al.,  
2004)  
  
ESPGHAN &  
ESPEN Guidelines 
(Koletzko, Goulet, 
Hunt, Krohn, &  
Shamir, 2005)  
British Association 
of Perinatal  
Medicine  
(British Association 
of Perinatal  
Medicine, 2016)  
Practice of PN 
in  
VLBW and  
ELBW Infants.  
(Embleton &  
Simmer, 2014)  
Neonatology/ 
Paediatrics 
Guidelines on 
PN  
(Fusch et 
al.,2009  
Amino acids 
(g/kg/day)  
3-4  
(preterm)  
1.5- 4  
(preterm)  
1.5- 3  
(term)  
2-2.5 after birth  
2.7-4 (day 5) 
(preterm)  
3 (day 5) (term)  
>2 (day 0)  
>3.5 (day 1-2)  
3.5-4 (day 3)  
  
  
Glucose 
(mg/kg/min)  
  4-8 (preterm)  
Max. 13 (term)  
4 – 12  
(preterm & term)  
7-12  
  
Max 12 (term)  
Lipid emulsion  
20%  
(g/kg/day)  
3 (preterm) 
Use 20% of 
lipid emulsion  
  
0.25 to 3- 4 
(preterm) 0.1 to 3-
4(term)  
2 (day 1) increase to  
maximum  
3.5-4  
>2 (day 0)  
3-4 (day 1-2-3)  
  
0.25 to 3-4  
(preterm)  
0.1 to 3-4 (term)  
Fluid 
(mL/kg/day)  
130-150 (<1.5kg)  
110-130 (1.5- 2kg)  
100 (2-10kg)  
80-90 (day 1)  
160-180 (day 6)  
(<1500g)  
60-80 (day 1)  
140-160 (day 6)  
(>1500g)  
60-120 (day 1)  
140-180 (day 6)  
(term)  
60-100 (day 1)  150 (day 3)  
Not exceed 
150175 first 
few days  
  
Energy needs 
(kcal/kg/day)  
90- 120 (preterm)  110-120 (preterm)  100-120 by 72  
hours of age  
  
60-80 (day 0)  
80-100 (day 1-
2)  
>100 (day 3)  
110-120 
preterm)  
90-100 (term)  
Na 
(mEq/kg/day)  
2-5 (2-5 
mmol/kg/day) 
(preterm & term)  
  
0-3 (0-3 
mmol/kg/day) 
(preterm & 
term)  
1-3 (1- 
3mmol/kg/day) 
from 48-72h of life 
and cautious during 
the two first days of  
life  
    
K 
(mEq/kg/day)  
2- 4 (2-  
4mmol/kg/day)  
(preterm & term)  
  
0-2 (0-2 
mmol/kg/day) first  
week of life  
(preterm& term)  
1-2 (1- 
2mmol/kg/day)  
from-72h of life  
  
    
Ca 
(mEq/kg/day)  
2-4 (1- 
2mmol/kg/day)  
(preterm)  
0.5-4 (0.25-  
2mmol/kg/day)  
(term)  
2-8(1-4mmol/kg/day)  
(preterm) 
2.6-6 (1.3-3 
mmol/kg/day)  
(term)  
3 (1.5mmol/kg/day)  
  
    
P 
(mmol/kg/day)  
1-2 (preterm)  
0.5- 2 (term)  
0.75-3mmol/kg/day  
(preterm)  
1-2.3 mmol/kg/day  
(term)  
0.18-0.2 
mmol/kg/day  
   
 PN= parenteral nutrition    
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2.2.2 Ordering Process  
Among neonatologists and pediatricians, there are a variety of practices for prescribing 
PN to infant patients; indeed, an effective method for avoiding errors during the ordering process 
is providing education to healthcare personnel (Boullata et al.,2014; Dutta et al.,2015). The British 
Association of Perinatal Medicine denotes that senior physicians should make the decision to 
initiate PN in neonate patients; however, their order forms should be reviewed by other healthcare 
personnel, including pharmacists, dietitians, and other clinicians (British Association of Perinatal 
Medicine, 2016).  Boullata (2012) instead suggests that when a nutritional support team (NST) is 
not available in the facility, other professionals such as knowledgeable nurses or physician’s 
assistants could prescribe PN (Boullata, 2012). In addition, order forms should be standardized, 
include the complete information of the patient, and be clearly written (Mirtallo et al., 2004).  
The 2003 Task Force for the Revision of Safe Practices for Parenteral Nutrition survey 
found widespread non-standardization of PN ordering practices within healthcare institutions. 
Additionally, the study noted critical errors in the units used in the prescription, omission errors, 
and miscommunication in the prescription (Mirtallo et al., 2004).  Standardized request forms 
specifying components and suppliers can help ensure that a validated set of procedures is used 
and that every step of these procedures is documented (British Association of Perinatal Medicine, 
2016). This standardization is especially vital in the event of an error as the documentation will 
allow PN professionals to determine the step of the process during which the mistake occurred. 
Uniformity in the ordering process can also avoid misinterpretation and confusion.  For this 
reason, it is suggested that a standardized ordering process must be implemented and permanent 
quality auditing must be performed to ensure the patient’s safety (Mirtallo et al., 2004).   
In addition, to standardization and education, surveillance and supportive technology can 
help improve the safety of the PN ordering process. Curtis (2018) argued that there are significant 
potential safety benefits to implementing computer-prescriber order entry (CPOE). CPOE can 
reduce the risk of potential transcription errors during PN prescribing and compounding. CPOE 
alerts the compounding professional of medication interactions and adjustments according to the 
patient’s medical condition (Curtis, 2018).  
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2.2.3 Compounding Process  
Compounding processes must take place in an aseptic pharmacy unit under a laminar flow 
hood, and changes to PN formulations at the patient’s bedside should be avoided (British 
Association of Perinatal Medicine, 2016; Embleton & Simmer, 2014). The pharmacist who is 
compounding the PN formulation is responsible for appropriately preparing, labelling, storing, 
dispensing, and distributing PN formulations (Mirtallo et al., 2004). Preparing PN formulation 
can be completed manually or automatically. Manual compounding consists of the admixture of 
the PN ingredients separately using syringes, needles or sterile transfer equipment performed by 
a health professional while automated compounding is performed by an automated compounding 
device (ACD), which uses “computer-assisted commands” and is “connected to special hardware 
housed with [a] sterile, disposable compounding set” (Mirtallo et al., 2004, p.S58). Automated 
compounding devices can admix the formulations in a sterile environment using disposable 
compounding sets, thereby further avoiding potential errors (Mirtallo et al., 2004; British 
Association of Perinatal Medicine, 2016).  
Automated compounding device can prevent compounding mistakes; however, Ayers et 
al.’s study (2014) aimed to describe pharmacists’ practices within hospitals noted errors when the 
ACD was used to compound PN. The compounding error rates were lower in the ACD compared 
to manual compounding (22% versus 37% respectively). Furthermore, this study showed common 
errors during the compounding process, including contamination, miscalculations, and bypassing 
the built-in safety check systems on ACDs (Ayers et al., 2014). For this reason, verifying and 
reviewing PN prescriptions is mandatory during this step whether the compounding is manual or 
automatic.  
 During the first step, the compounding pharmacist should verify that the PN order is error-
free and perform a clinical and pharmaceutical review to ensure the appropriateness and 
compatibility of the PN elements (Boullata, 2012). The ASPEN guidelines highlight that the 
formulation and unintentional delivery of macro precipitates solids, resulting from the addition of 
incompatible salt combinations to the PN formulation, or liquids, which develop when there is a 
phase separation with the liberation of free oil in the TPN formulation, exceeding five microns 
constitute a hazardous threat to infants’ lives and may result in embolic deaths. These guidelines 
recommend that in order to prevent the potential formation of dibasic calcium phosphate 
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(CaHPO4), one of the most threating solid precipitations, the phosphate should be added first, and 
at the end of compounding, the use of calcium gluconate is preferred (Mirtallo et al., 2004).  
During and after the compounding process, the PN formulation must be gravimetrically, 
chemically and refractometrically analyzed and in-process tested following the guidelines for 
sterile product admixture (Mirtallo et al.,2004). PN bags should be labelled with clear and accurate 
information describing exactly what the neonate patient is receiving (Boullata, 2012; Mirtallo et 
al., 2004). These labels must include the route of administration, administration date, beyond-use 
date, dosing weight, and rate of infusion (Mirtallo et al., 2004).  Finally, when not in use, PN 
formulations should be kept in a refrigerator, and if the patient is going to receive a refrigerated 
PN, it should be removed from the refrigerator 30 to 60 minutes prior to administration to allow 
the solution to reach room temperature (British Association of Perinatal Medicine, 2016; 
Embleton & Simmer, 2014; Boullata, 2012).  
2.2.4 Additions to PN formulations  
  Concerns and questions have arisen with respect to the appropriateness of adding other 
medications to the PN formulation.  Current guidelines recommend avoiding adding other 
medication to PN formulations due to the complexity of the PN itself (British Association of 
Perinatal Medicine, 2016; Embleton & Simmer,2014; Cohen, 2012; Mirtallo et al., 2004). 
However, if the administration of other medication is mandatory, the pharmacist is responsible 
for assuring that the admixture is safe, stable, and compatible (Mirtallo et al., 2004). Supporting 
this recommendation, the ASPEN clinical guidelines suggest that heparin should not be added to 
PN formulations even if the purpose of this procedure is to prevent the potential risk of thrombosis 
(Boullata et al., 2014).   
Two contradictory randomized, double-blind, controlled studies in neonate patients 
receiving PN examined the effects of heparin when used to prevent catheter blockage. Kamala,  
Boo, Cheah, and Birinder’s study (2002) aimed to determine if the addition of heparin at 1 IU/ml 
dose to the TPN emulsion would prevent the blockage of peripherally inserted central catheters 
(PICC) in neonate patients.  They found that there were no statistical differences between the 
group of infants that received heparin and the group which did not receive heparin with respect to 
the incidence of blocked catheters, catheter-related sepsis, hypertriglyceridemia, 
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hyperbilirubinemia, coagulopathy or intraventricular hemorrhage (Kamala, Boo, Cheah, & 
Birinder, 2002).   
Conversely, Uslu, Ozdemir, Comert, Bolat, and Nuhoglu’s study (2010) that aimed to 
evaluate the effect of heparin on peripherally inserted percutaneous central venous catheter 
patency and catheter occlusion and came to notably different conclusions. This study found that 
the duration of catheter patency on neonates who received heparin at 0.5 IU/kg/hour was longer 
when compared to the non-heparin group. These results were noted to meet the criteria for 
statistical significance. In addition, this study found that there were a higher number of neonates 
on heparin group that could complete the TPN treatment compared to the neonates in the non-
heparin group. Finally, the incidence of catheter occlusion in the heparin group was lower 
compared to the non-heparin group (Uslu, Ozdemir, Comert, Bolat, & Nuhoglu, 2010).   
To address the controversial use of heparin to prevent thromboembolic complications in 
patients receiving PN treatment, the ASPEN guidelines recommend that alternatives to heparin 
be used to prevent thromboembolic complications. These alternatives must consider catheter type, 
venous access line care, and line placement. This guideline highlights that polyurethane catheters 
are less prone to catheter blockage than polyethylene catheters (Boullata et al., 2014). Thus, the 
guideline recommends that polyurethane catheters are used as an alternative method of adding 
heparin to the formulation for preventing blockage in neonate patients on PN treatment.  
2.2.5 Administrating PN  
Procedurally, it is suggested that PN should be administered in neonate patients using a 
central line preferably positioned at the inferior vena cava or the superior vena cava using an 
umbilical venous catheter or PICC if the PN is expected to be delivered for more than a few days 
and if the PN formulation osmolarity is > 1000 mOsm/L (British Association of Perinatal 
Medicine, 2016; Mirtallo et al., 2004). Despite this, some guidelines recommend that peripheral 
lines be used whenever possible (Fusch et al., 2009). According to the Nutritional Care of Preterm 
Infants Guidelines, if the PN is composed of 12.5 to 15% dextrose, it should be administered using 
a central line and that PN within the range of 800 to 1200 mOsm/L should be administered 
peripherally (Embleton & Simmer ,2014). Conversely, ASPEN clinical guidelines recommend 
that PN with osmolarity up to 900 mOsm/L can be administered with a peripheral line without 
causing any significant risk to the infant patient (Boullata et al., 2014).  This lack of consistency 
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between guidelines’ recommendations with respect to the safe upper limit of osmolarity for PN 
administered through a peripheral cannulae could be, as Boullata et al. argues, due to a shortage 
of evidence to support the ideal safe osmolality, since most relevant studies were designed as 
observational and more randomized control trials are needed (Boullata et al., 2014).     
Although the placement procedure of a peripheral cannulae can be easier compared to 
central venous catheter placement, which requires an experienced professional and specialized 
technique, the use of peripheral cannulae to deliver PN is associated with some potential 
complications, such as subcutaneous infiltration which can cause skin damage such as ulceration, 
infection, and scarring, and thrombophlebitis associated with a high osmolarity of the PN 
formulation (Ainsworth & Mcguire, 2015; Boullata et al., 2014 ; Mirtallo et al., 2004). Two recent 
randomized control trials compared the effectiveness of the percutaneous central venous lines 
versus peripheral intravenous lines. Thus, Barria, Lorca, and Munoz’s study (2007) of seventyfour 
neonate patients who required intravenous therapy (IV) for more than five days found a 
statistically higher incidence of phlebitis in the group who used a peripheral intravenous catheter 
(PIV) compared with the PICC group (40.5% versus 10.8% respectively). Furthermore, the PIV 
group presented three cases of tissue necrosis by fluid extravasation. There were no differences 
with respect to the length of stay and the incidence of sepsis (Barría, Lorca, & Muñoz, 2007).   
Similarly, Wilson, Verklan, and Kennedy’s study (2007) of ninety-six VLBW infants who 
required IV therapy for at least five days, found that there were no significant differences 
regarding systemic infection, death, and length of stay between the PIV group compared to the 
percutaneous central venous line (PCVL); however, the number of skin punctures was 
significantly greater in the PIV group compared to the PCVL group (14.5 versus 9 respectively) 
(Wilson, Verklan, & Kennedy, 2007).   
To support the previous findings, a long-standing randomized trial of forty-nine neonate 
patients who received PN for at least five days compared sepsis rates between patients receiving 
this treatment through PCVL and peripheral cannulae. This study found that there were no 
statistical differences between both groups (46% versus 40% respectively) regarding sepsis rates. 
Nonetheless, there was a statistically higher percentage of median PN shortfall in the PCVL group 
compared to the peripheral cannulae group (10.3% compared to 3.2% respectively). The main 
reasons for the PN shortfall were technical problems after changing bags in the PCVL group and 
a lack of venous access in the peripheral cannulae group (Ainsworth, Furness, & Fenton, 2001).  
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The findings of these three trials comparing the use of central and peripheral lines suggest that the 
use of peripheral lines can be significantly associated with critical complications; however, the 
bloodstream infection rate as a complication of peripheral lines was not significantly different 
between venous access sites.   
 Ainsworth and Mcguire’ systematic review (2015) of six randomized control trials 
evaluated the effects of the use of central versus peripheral lines to deliver PN on the neonate’s 
development, nutrition, infection, and skin damage. One reviewed study found that the use of a 
central line increased the nutrient input in the patient receiving PN, and three studies found that 
the use of a central line decreased the number of catheters/cannulae needed to deliver the PN.  
Finally, the author concluded that more trials are needed to determine which venous access line 
is better in terms of the nutrition, growth, and development of the patient (Ainsworth & Mcguire, 
2015). Ainsworth and Mcguire noted that recent trials are needed to determine which venous 
access site provides advantages in term of growth and development and presents fewer 
complications for the patient. Central venous catheters’ complications will be described later in 
the review in the section that discusses the complications associated with PN.  
In addition to the central or peripheral access point, in-line filters must be discussed during 
PN administration. In-line filters can help reduce micro precipitates, microorganisms, pyrogens, 
and air during PN administration (Mirtallo et al., 2004; British Association of Perinatal Medicine, 
2016; Embleton & Simmer, 2014).  ASPEN guidelines recommend the 0.22 micron in-line filter 
for 2-in-1 solutions (amino acids and dextrose admixture); while a 1.2-micron filter is suitable for 
3-in-1 emulsion or total nutrient admixtures (amino acid, dextrose, and lipids emulsion). The 
authors outline that in-line filters are extremely useful for preventing potential complications; 
however, they have limitations, including causing “decrease[d] flow rates, clogs, or airlocks.” An 
additional recommendation described in these guidelines suggests using an electronic infusion 
pump that features safety alarms for air, pressure, rate cycling, and free flow protection features 
to ensure that the accurate volume of PN is provided and safely administered (Mirtallo et al., 
2004).   
Further addressing the administration process, the 2003 Task Force Survey of PN Practices 
found critical issues with PN administration, including PN rate and volume errors, administration 
to the incorrect recipient patient, and improper venous access line use (Mirtallo et al., 2004). To 
prevent these errors, the British Association of Perinatal Medicine (2016) recommends that prior 
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to delivering  PN treatment to the patient, the professional administering the formulation should 
ensure that there are no errors in the identification of the patient with two other identifiers and 
verify that the venous access site of administration, labels, aspects of the PN formulation, and 
beyond-use date (BUD) are correct (British Association of Perinatal Medicine, 2016). BUD is 
defined by the United States Pharmacopeia chapter <795> (USP) as the date which a compounded 
sterile preparation possesses the same properties and characteristics that it did at the time of 
compounding (McElhiney, 2009). In addition to these recommendations, ASPEN guidelines 
provide details to be verified during the PN bag visual inspection. This inspection should 
determine the presence of leaks, changes in colour, cracking of emulsion, and turbidity of the PN 
emulsion. If any of these signs are present in the PN formulation, it should not be administered, 
or administration should be suspended immediately (Mirtallo et al., 2004).  
During the infusion step, in order to avoid potentially hazardous peroxide generation in PN 
formulations, the Nutritional Care of Preterm Infants Guidelines recommend that PN bags should 
be protected from the light and use amber tubing (Embleton & Simmer, 2014). Peroxides are a 
product of oxidation which have the potential to cause an oxidative issue with general or local 
repercussions in neonates who have immature antioxidant defences (Lavoie, Belanger, Spalinger, 
& Chessex, 1997). A randomized trial in fifty-nine preterm neonates aimed to evaluate the effects 
of shielding TPN formulation from the light on blood glucose and triglyceride (TG) 
concentrations. The photoprotection was applied in the compounding and delivery process using 
a covering for the PN bags (protecting amino-acid, dextrose, and lipid emulsion) and syringes, 
and amber tubing. This study found over the first nine days of life that the light-exposed (LE) 
TPN formulation group presented a significantly higher mean blood glucose levels compared to 
the light-protected (LP) TPN group (6.6 (SD 0.2) mM versus 6.0 (SD 0.1) mM respectively). 
Furthermore, at eight days of life, the LE group presented significantly higher mean plasma TG 
levels compared to the LP group (1.5 (SD 0.3) versus 0.9 (SD 0.1) mM respectively) (Khashu, 
Harrison, Lalari, Lavoie, & Chessex, 2009).   
In contrast to Khashu et al.’s findings, a randomized controlled trial in VLBW neonates 
that aimed to determine if the photoprotection of PN can reduce the rates of bronchopulmonary 
dysplasia (BPD) and death, did not find any statistical differences between the LE group compared 
to the LP group with respect to BPD and death rates at 28 days of life. Furthermore, a multivariate 
analysis showed no significant effect from shielding PN from the light on BPD and death (Laborie 
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et al., 2015). Despite these contradictory findings, the British Association of Perinatal Medicine 
(2016) recommends photoprotection of PN bags and giving sets (British Association of Perinatal 
Medicine, 2016).  
If there is suspected contamination or if the formulation has been compromised after PN 
administration, the ASPEN guidelines recommend that PN bags should be changed using aseptic 
procedures. This guide suggests the 3-in-1 formulation must be changed every 24 hours, and 2-
in1 solutions must be changed every 72 hours. Furthermore, this guideline recommends that for 
intravenous fat emulsion (IVFE) that is an admixture to compound TPN formulation, the safe 
BUD for its delivery should be 24 hours (Mirtallo et al., 2004). Additionally, Boullata et al. (2014) 
suggest the BUD for IVFE delivered separately in the original container should be 12 to 24 hours 
and the BUD for repackaged IVFE should be 12 hours (Boullata et at., 2014).   
2.2.6 Monitoring patients on PN   
Due to the high fluid volume, high body water content, immature regulatory mechanisms 
and low blood volume of preterm neonates, cautious monitoring is required in patients on PN 
treatment (Fusch et al., 2009). Anthropometrically and biochemically monitoring the patient 
receiving PN treatment allows medical professionals to evaluate the efficacy of the PN treatment, 
prevent potential complications, and determine the clinical condition and clinical outcomes of the 
patient (Mirtallo et al., 2004). According to the European Society for Paediatric Gastroenterology, 
Hepatology and Nutrition (ESPGHAN) and the European Society for Clinical Nutrition and 
Metabolism (ESPEN) guidelines, biochemical monitoring allows for the administering 
professional to assess the patient’s clinical and nutritional status, and the anthropometric 
assessment enables the clinician to evaluate the nutritional status of the patient (Koletzko, Goulet, 
Hunt, Krohn, & Shamir, 2005).   
The Nutritional Care of Preterm Infants Guidelines recommends measuring the infant’s 
weight daily and measuring their length weekly in order to evaluate the nutritional support and 
growth in the patient. The ideal nutritional support for premature infants will provide optimal 
growth and allow them to obtain nutrient accretion similar to a fetus at the same gestational age. 
This guideline recommends that in order to promote adequate growth in VLBW neonates, the PN 
should provide 120kcal/kg/day of energy and 3.8g/kg/day of protein by the first seven days of 
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life. Finally, this guideline recommends the use of birth weight-bases intrauterine curves to 
monitor growth in preterm infants at the NICUs (Poindexter, 2014).  
 Among PN guidelines, there is consensus that infants who are receiving PN should 
undergo a complete evaluation of electrolytes, blood glucose test, fluid balance test, sepsis 
monitoring, and anthropometric measurements, such as body weight, length, head circumference 
( Mirtallo et al., 2004; British Association of Perinatal Medicine, 2016; Embleton & Simmer , 
2014 ; Fusch et al., 2009).  However, according to the Nutritional Care of Preterm Infants: 
Scientific Basis and Practical-Guidelines, the frequency and method of monitoring to determine 
the efficacy of the PN treatment depends on the clinical condition of the patient and duration of 
the PN treatment, and this frequency varies from NICU to NICU (Embleton & Simmer , 2014;  
Pedrón, 2017). Monitoring the patient on PN not only varies between NICUs but varies within 
published guidelines as well. Table 2.2 shows the recommended frequency of anthropometric and 
biochemical assessments of patients receiving PN treatment from the British Association of 
Perinatal Medicine guidelines and two comparable sources.  
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Table 2.2 Frequency of anthropometric and biochemical assessment of neonate patients who are 
 receiving TPN 
Assessments  British Association of  
Perinatal Medicine  
(British Association of Perinatal  
Medicine, 2016)  
Practice of Parenteral  
Nutrition in VLBW and  
ELBW Infants (Embleton  
& Simmer , 2014)  
Neonatology/Paediatrics 
Guidelines on Parenteral  
Nutrition (Fusch et al.,  
2009)  
  1
st week of PN  Stable PN    Initial 
phase of 
PN  
Medium &  
Long-term PN  
Anthropometric 
assessment 
wt/length/head 
circumference  
Daily (wt)  
Weekly  
(length & head 
circumference)  
Twice weekly  
(wt)  
Weekly  
(length & head  
circumference)  
  
Daily or alternate days (wt) 
Weekly (length & head 
circumference)  
  Weekly  
Fluid balance  Daily  Twice weekly     Daily  Weekly  
Full blood count  weekly  weekly        
Blood glucose   q6h to q8h   Daily   Daily (first 3-4 days)  Daily  Weekly  
Electrolytes  Daily  Twice weekly  Daily (first 3-4 days)  Daily    
Hepatic 
enzymes (LFTs, 
Alkaline 
phosphatase)  
Daily or twice 
weekly  
Weekly  Weekly    Y-GT weekly 
Alkaline 
phosphatase 
every 2 weeks  
Urea, Creatinine  Daily  Twice weekly      Weekly  
Triglycerides 
Cholesterol  
Twice weekly  Twice weekly  Twice weekly (or if 
lipemic serum)  
    
Proteins/ 
Albumin  
Daily  Twice weekly        
Bilirubin  Daily  Weekly        
Mineral  
&Vitamins  
  Monthly (long 
term PN)  
      
       q6h= every 6 hours          q8h= every 8 hours  
  
2.2.7 Weaning PN  
 A wide range of practices exists between clinical guideline recommendations regarding 
the indications to cease PN and begin enteral nutrition in infants on PN treatment. A retrospective 
chart review on neonates below 32 weeks of gestational age which aimed to identify during which 
phase of an infant’s stay they are most likely to present with poor growth and potential growth 
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failure (GF) (discharge weight below the 10th percentile). The patient’s stay was divided into three 
phases: first or full PN, second or transitional PN and enteral nutrition (EN), and third phase or 
full EN. During the transitional phase, PN infusion was decreased when trophic feeds exceeded  
20ml/kg/day to reach a total of fluids at 140ml/kg/day. PN was discontinued when EN reached 
100mL/kg/day. This study found that 49 percent of neonates were discharged with GF, that the 
poor growth incidence was highest during the transition phase (46%), and that protein intake 
decreased as PN was weaned (Miller et al., 2014).   
Based on this study, the British Association of Perinatal Medicine recommended that PN 
should be weaned when 75 percent of enteral nutrition is tolerated. In preterm infants, a milk 
intake of at least 120ml/kg/day is suggested (British Association of Perinatal Medicine, 2016). 
Conversely, the Nutritional Care of Preterm Infants Guideline recommends that neonates reach 
higher enteral nutrition before stopping PN. This guide recommends that when 125-150ml/kg/day 
of enteral nutrition is tolerated, PN should be weaned (in the first few days, the neonate should 
not exceed 150 to 175 ml/kg/day of total fluid intake) (Embleton & Simmer, 2014).   
 In their review, Dutta et al. (2015) recommend providing trophic feeds or small volumes 
of milk, approximately 10 to 15ml/kg/day starting within 24 hours of life. This trophic feed should 
be provided to progressively introduce enteral feeds, and extreme caution should be exercised 
when administering the feed to ELBW or extremely preterm neonates. However, in cases of 
intestinal obstruction or ileus trophic feeds, this recommendation is contraindicated (Dutta et al., 
2015). Dutta et al. based their recommendation of the early introduction of the trophic feed on 
two systematic reviews of the level of evidence 1a, a systematic review of a homogeneity of 
randomized controlled trials (Oxford Centre for Evidence-Based Medicine-Levels of Evidence, 
2009).    
The first systematic review of nine randomized or quasi-randomized  controlled trials in 
VLBW and ELWB neonates that aimed to evaluate the effect of early trophic versus enteral 
fasting on feed tolerance, growth and development, and incidence of necrotizing enterocolitis 
(NEC) and mortality, found that in six studies the early introduction of the trophic feeds (15 to 
25ml/kg/day on day one of life) did not affect the feed tolerance (time to establish full enteral 
feeding) in the trophic feeds group compared to the fasting group. In five of the nine trials there 
were not significant effects on the days it took the neonates to regain their birth weight and on the 
incidence of NEC respectively (Morgan, Bombell, & Mcguire, 1997). The second systematic 
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review of nine randomized controlled trials in VLBW infants aimed to determine the effect of 
early versus late enteral nutrition (after four days of life) on the incidence of NEC, mortality, and 
morbidity found that in eight trials the early introduction of enteral feeds did not increase the risk 
of NEC. In six trials there were not significant effect on feed intolerance (Morgan, Young, & 
Mcguire, 2011).   
 This inconsistency in PN practice requires further research to develop PN 
recommendations that are safe for VLBW and ELBW infants (Adamkin & Radmacher, 2014). 
Similarly, Embleton and Simmer (2014) highlight that guidelines’ recommendations are based 
primarily on expert opinion and rely on limited evidence as only a few large randomized 
controlled trials have been conducted (Embleton & Simmer, 2014) suggesting that, although 
guidelines are an invaluable resource for the personnel delivering PN at the NICUs, there are 
opportunities for improvement.  
2.3 PN Complications and expenses associated with PN administration  
While the benefits of providing PN to neonates is obvious, there can be undesirable 
complications if administered improperly or if the concentrations of ingredients are too high 
(Dudrick, Macfadyen Jr, Van Buren, Ruberg, & Maynard, 1972). These oversights may cause 
harmful complications, described in the pertinent literature, which result from PN delivery 
responsibility being placed on health care workers unfamiliar with the delivery guidelines and 
processes (Mirtallo et al., 2004). This risk of complication is why administering PN is a complex 
procedure requiring significant training for health care personnel who administer and formulate 
the medication. Among the complications associated with PN treatment, the literature describes 
negative pharmaceutical interactions, including potential precipitation of salt caused by the 
interaction between calcium and phosphate, described previously in this review, venous access 
line associated sepsis, hyperglycemia, hypoglycemia, parenteral nutrition-associated cholestasis 
(PNAC) and other complications (British Association of Perinatal Medicine, 2016; Mirtallo et al., 
2004; Uthaya & Modi, 2014).   
Since PN consists of protein, dextrose, lipids, trace elements, vitamins, and minerals, it 
can encourage microbial growth when contaminated by microbes, thereby leading to sepsis in 
neonates (Tresoldi et al., 2000). Furthermore, microbial contamination of the delivery venous 
access lines or catheters can result in the introduction of pathogens into neonates (Sitges-Serra, 
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Linares, Perez, Jaurrieta, & Lorente, 1985). These lines can be either peripheral or central venous 
access sites. Peripheral line complications were described previously in this review. The most 
important complication associated with the central venous catheter described in the literature is 
the nosocomial infection (Ainsworth, & Mcguire, 2015).   
Catheter-related bloodstream infections (CRBSI) are defined by the American Academy 
of Pediatrics (AAP) as a positive blood culture in the presence of a central venous catheter after 
another source of infection in a symptomatic patient has been excluded (i.e., fever, chills, and /or 
hypotension) (Oliveira, Nasr, Brindle, & Wales, 2012).  The AAP’s guidelines for the prevention 
of intravascular catheter-related infection outlines that CRBSI is confirmed when “a positive 
semiquantitative (>15 CFU/catheter segment) or quantitative (>103 CFU/catheter segment 
catheter) culture whereby the same organism (species and antibiogram) is isolated from the 
catheter segment and the peripheral blood” (O'Grady et al., 2002, p. 2).   
The Garland et al.’s study (2008), which aimed to define the pathogenesis of CRBSI in 
eighty-two neonates with PICC placed in situ for a mean of twenty days (SD 12), reported twenty-
three of the neonates were diagnosed with nosocomial bloodstream infection (BSI), and fifteen of 
these cases (18%) were reported to include either definite or probable CRBSI. The microorganism 
found in fourteen cases was coagulase-negative staphylococci. This study reported that 67%, 20% 
and 13% of the CRBSI cases were caused by intraluminal, extraluminal, and indeterminate 
contamination respectively (Garland et al., 2008).  Another prospective study which aimed to 
identify the incidence of nosocomial infection (NI) (infection occurring 48 hours after admission) 
in Danish NICUs found that the incidence of NI was 13.2 per 100 patients and 8.8 per 1000 patient 
days. On the other hand, the incidence of BSI was 7.6 per 100 patients and 5.1 per 1000 hospital 
days (Olsen et al., 2009).   
Other complications associated with PN administration are metabolic complications 
including hypoglycemia and hyperglycemia. The AAP defines hypoglycemia as a medical 
condition that requires an immediate parenteral treatment when the serum concentration of 
glucose is less than 45mg/dL (2.5mmol/L) before each feeding in symptomatic neonates (non-
specific clinical signs include abnormal respiratory patterns, cardiovascular signs, and neurologic 
findings) and less than 25mg/dL(1.3 mmol/L) at birth to 4 hours of age or 35mg/dL (1.9 mmol/L) 
from 4 to 24 hours of age in asymptomatic neonates (Adamkin, 2011). However, there is still 
disagreement regarding the definition of hypoglycemia. Currently, Saugstad (2017) describes that 
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hypoglycemia is most accurately defined as when a patient’s blood glucose level is less than 
47mg/dL (2.6 mmol/L) (Saugstad, 2017).  Adamkin describes the method used to test blood 
glucose levels in patients and notes that at low glucose concentration test-strips have a great 
variation compared to the actual plasma glucose concentrations. For this reason, results must be 
confirmed by a rapid laboratory blood or plasma concentration test (Adamkin, 2011).  
 Pildes, Forbes, Apos, Connor, and Cornblath’s research (1967) found that 14 of 244 LBW 
infants participating in its study had two or more blood glucose values below 20mg/dL (1.11 
mmol/L) during the first five days of life, an incidence of 5.7 %. Furthermore, the study describes 
symptoms including eye rolling, weak or high-pitched crying, sweating and poor feeding in 
hypoglycemic patients (Pildes, Forbes, Apos, Connor, & Cornblath, 1967).  Another study, which 
defined hypoglycemia as a blood glucose level below 30mg/dL (1.66mmol/L), examined neonates 
who were tested for blood glucose levels at birth, after three to four hours after birth (fasting) and 
at the third or fourth day after birth (fasting). This study found that 184 out of 1617 patients 
experienced hypoglycemia (11% of expected incidence) during the first three to six hours after 
birth. In addition, this study found that neonates who were small for their gestational age group 
had the highest incidence of hypoglycemia, 27 out of 70 cases (32%), compared to neonates who 
were considered the appropriate size for their gestational age, 23 out of 226 cases (10%), and 
infants who were large for their gestational age, 9 out of 78 cases (11%) (Lubchenco & Bard, 
1971).   
Conversely, the AAP defines hyperglycemia in preterm infants as occurring when their 
plasma glucose level is over 150mg/dL (8.3mmol/L) or over 125mg/dL (6.9 mmol/L) in blood 
glucose concentrations (Rozance & Hay, 2010).  The Bryan, Wei, Hamilton, Chance, and Swyer’s 
study (1973), which aimed to evaluate the effects of a dextrose fibrin hydrolysate solution in 
neonates less than 1300 grams, found that seven out of eleven patients who received dextrose 10% 
with 3.5% fibrin hydrolysate and only dextrose solution (23%) had blood glucose levels over 
150mg/dL (Bryan H, Wei, Hamilton, Chance, & Swyer, 1973). Furthermore, Dweck, Brans, 
Summer, and Cassady (1976) found that 43 of 50 (86%) of neonates weighing less than 1100 
grams presented plasma glucose levels over 125mg/dL, and 36 of those 43 (84%) of infants had 
one or more serum glucose level over 300mg/dL (Dweck, Brans, Sumners, & Cassady, 1976).   
Lastly, another complication associated with parenteral nutrition administration is PNAC. 
Klein, Ravenis, Kusenda and Scavo (2010) outlined that the term PNAC “is commonly used in 
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publications to indicate PN associated hyperbilirubinemia with cholestasis but actual 
determinations of cholestasis are not often reported” (Klein, Ravenis, Kusenda, & Scavo, 2010, 
p. 1685). The AAP defines abnormal conjugated bilirubin as a conjugated bilirubin concentration 
over 1mg/dL (17.1umol/L) when the total bilirubin (TB) is at or below 5mg/dL (85umol/L) or 
over 20% of the TB when the TB is higher than 5mg/dL (Maisels et al., 2004).  In the reviewed 
scientific literature, clinical trials of infant patients receiving PN defined PNAC conjugated 
bilirubin levels as 1.8mg/dL (30.8umol/L), over 2mg/dL (34.2umol/L), and 2.9mg/dL 
(49.6umol/L) (Puligandla et al., 2004; Wright, Ernst, Gaylord, Dawson, & Burnette, 2003; 
Köglmeier, Day, & Puntis, 2008).   
Klein et al. (2010) noted that PNAC is diagnosed by exclusion by generating a differential 
diagnosis from obstructive causes, primary liver disease, metabolic liver disease, and sepsis. 
Furthermore, the author describes that diagnostic tests (hepatobiliary ultrasound, hepatobiliary 
scintigraphy, hepatobiliary magnetic resonance imaging, and liver biopsy), biochemical markers 
(conjugated bilirubin ≥2mg/dL) and clinical signs (jaundice, pale stools, itchiness, hepatomegaly, 
splenomegaly, ascites) are considered during the evaluation of PNAC (Klein, Ravenis, Kusenda, 
& Scavo, 2010).   
Puligandla et al.’s study (2004) aimed to compare the outcomes of intrauterine growth-
restricted infants with gastroschisis to those without growth restriction receiving TPN. This study 
found that 26 out of 76 (34%) of patients with less than 37 weeks of gestational age (GA) had 
PNAC compared to 5 out of 37 (13.5%) of patients with more than 37 weeks of GA (Puligandla 
et al., 2004).  Conversely, Wright, Erns, Gaylord, Dawson, and Burnette’s study (2003), which 
aimed to compare the incidence of PNAC in infant patients who received PN amino-acids 
Aminosyn Pediatric formula and Trophamine, found that 24 out of 661 patients developed PNAC 
(3.6%). The same study found a PNAC incidence of 17% in infants who received PN for more 
than 21 days as 24 out of 141 infants developed this complication (Wright, Ernst, Gaylord, 
Dawson, & Burnette, 2003).   
Aside from the harmful complications, PN represents a significant allocation of funds 
within the health care system of each country. Based on research conducted in NICUs in the 
United States, the average stay is 42.2 days which costs an average of $65,600 per neonate 
(Russell et al., 2007). The costs and length of stay can be higher for ELBW neonates. 
Nevertheless, in their quality improvement study, Boitano, Bojak, Mccloskey, Mccaul, and 
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Mcdonough (2010) found that implementing ASPEN practice guidelines, including revising the 
PN order form, providing additional education to staff, and initiating PN rounds in the institution, 
provided both quality improvements and cost savings. In total, these changes provided savings of 
$5.3 million in PN charges and $107,000 in pharmacy expenses (Boitano, Bojak, Mccloskey, 
Mccaul, & Mcdonough, 2010).  
 Due to the mortality, morbidity, and the high costs associated with PN administration, 
steps to standardize PN formulations and guidelines for its delivery according to the weight of the 
neonate have been recommended. Standardization of PN bags means that they can be mass 
produced which would thereby result in decreased costs (Bolisetty, Osborn, Sinn, & Lui, 2014;  
Uthaya & Modi, 2014). According to the Yeung, Smyth, Maheshwari, and Shah’s study (2003), 
the cost of standardizing TPN bags in an Australian NICU was 30% lower compared to the cost 
of using individualized bags ($88 per bag versus $130 respectively) (Yeung, Smyth, Maheshwari, 
Shah, 2003).   
2.4 Standardized PN versus Tailored PN  
Standardized PN bags can decrease issues such as contamination and errors in the 
formulation or concentration of the ingredients, are readily available to initiate PN within the first 
hour of life of the neonate patient, and  can optimize clinical outcomes and reduce the risk of 
complications (Berlana et al., 2014; Turpin et al., 2012; British Association of Perinatal Medicine,  
2016). Thus, Yeung et al.’s study (2003) aimed to determine the difference in nutrient intake and 
biochemical response between neonates less than 33 weeks of gestational age who received 
standardized TPN compared to neonates who received individualized TPN from day two to seven 
of life. This study found that neonates who received standardized TPN formulations received 
significantly more protein daily and cumulatively during the first week of life compared to 
neonates receiving individualized TPN (13.6g/kg versus 9.6g/kg). Infants receiving standardized 
TPN received 25% more calcium and phosphate from day three, and less sodium and no potassium 
on day two (Yeung et al., 2003).  Furthermore, Rigo et al. (2012) found that the use of commercial 
three-chamber PN bags, which contain amino acids, dextrose, and lipids, ensures ease of bag 
manipulation. This was measured by visual analog scale (VAS) (the method used to measure the 
quality of practical handling and ease of use). The VAS scores were higher for bag manipulation 
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and prescription-to-infusion time than TPN ward compounding. In addition, there were no adverse 
events related to the PN treatment (Rigo et al., 2012).  
This is not to say that individualized PN formulations will not have a place in the arsenal 
of attending physicians. In fact, a study found that those receiving individualized PN formulations 
experienced significantly higher protein intake during the first week of life compared to the 
standardized group (23.2/kg/week versus 19.6g/kg/week respectively). Furthermore, this study 
found significantly higher lipid, glucose, and energy intake during the first and second week of 
life in the early individualized group compared to the standardized group. Another finding of this 
study was that the time to regain birth weight was significantly shorter in the individualized group 
compared to the standardized group (10.4 days versus 12.8 days) (Eleni-Dit-Trolli et al., 2009).   
2.5 PN practices in developed countries  
In developed countries, there had been numerous improvements in PN practices. This 
includes annual reviewing and auditing with recommendations to improve PN processes. A study, 
which aimed to describe experiences with nutrition- NEC in a focus group as part of a quality 
improvement project in NICUs in the United States of America (USA), reported that after eight 
potential better practices (PBPs) were applied, patients in all three participating institutions 
demonstrated significant improvements. This project employed a self-assessment survey for 
health personnel, retrospective chart reviews of VLBW neonates, a literature review, and 
benchmarking with centers of excellence (centers with a low rate of NEC) in order to develop the 
PBPs. One example of these PBPs was that the “initiation of TPN should be done as soon as the 
infant is medically stabilized, preferably within the first 24 hours of life” (Kuzma-O'Reilly et al., 
2003, p. e464).  
  Additionally, this study found that patients in the group that implemented the PBPs 
experienced improvements in growth patterns compared with the baseline group (83% versus 98% 
of infants discharged with <10th percentile respectively). Also, infants in the group that 
implemented the PBPs reached full enteral nutrition in a shorter time compared to the baseline 
group (23.7 versus 34 days respectively). Finally, the intervention group had a decreased 
incidence of NEC in two out of three institutions (from 16% to 6% and from 6% to 4%) (Kuzma-
O'Reilly et al., 2003) demonstrating improvements in their nutrition support practice.  
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A telephone survey completed in the United Kingdom (UK) on PN administration and 
management in 57 NICUs showed diverse PN practices, knowledge, and management of 
complications between professionals in the UK, Wales and Scotland. The response rate obtained 
was 95% (54 out of 57 NICUs). Regarding the initiation of amino-acids, 24%, 43%, and 33% of 
NICUs begin amino-acids from 0 to 23 hours of life, between 24 to 48 hours of life, and after 48 
hours of life respectively.  Eighty-three percent of the NICUs used Intralipid 20%. Also, 6 %, 
48%, and 46% of the units initiated parenteral lipids from 0 to 23 hours, 24 to 48 hours, and after 
48 hours of life respectively. It was also noted that there was a lack of knowledge of nutritional 
support among physicians.  Two-thirds of middle-grade doctors (35 out of 54) were unaware of 
the concentration of amino-acid used in PN in their units while the other one third  (19 out of 54) 
noted the maximum concentration of amino-acid used to begin PN treatment is 3g/kg/day (6 
NICUs), 2.5g/kg/day (12 NICUs), and 2g/kg/day (1 NICU). Even though all units (54 out of 54) 
had a PN protocol, the authors highlighted the need for a standard evidence-based PN guideline 
across the UK to improve PN therapy practices. It was predicted that doctors would follow the 
recommended guidelines if they were precise and clearly stated (Ahmed, Irwin, & Tuthill, 2004).  
 Another survey on the delivery of PN in neonatal units in 67 hospitals in Australia 
reported that 40% of hospitals had PN teams and 74% noted that they had a PN protocol. 
Inaccessible or non-functional gastrointestinal (GI) tract was the most common reason to initiate 
PN treatment.  Sixty percent of the participants reported that PN is ceased when at least half of 
the patient’s requirements are met enterally or orally. Furthermore, 55% of the interviewees noted 
that patients on PN were biochemically monitored daily, 28% described monitoring patients three 
to four times per week, and 6% noted performing monitoring one to two times per week. Finally, 
the authors stated that the PN practices in the NICUs met the guideline recommendations; 
however, there is a significant variation in practices among physicians where there is no evidence 
to support the recommendations (Ali, Chapman-Kiddell, & Reeves, 2007).  
 In face-to-face or telephone interviews with nutrition and nursery staff at eight NICUs in 
North Carolina, it was found that the most common educational degree reported was Registered 
Dietitian. Pharmacists were the professionals responsible for compounding the PN formulation. 
Additional findings noted that six of the NICUs developed their own paper order forms to 
formulate PN containing a wide range of nutrition decision support; however, most of the self-
reported medical errors were related to misinterpretation of the form, improper transcription or 
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procedural errors. The author highlighted that electronic PN management could reduce PN 
practice errors by 50 % (Porcelli, 2004). A study at Geneva University Hospital found that, while 
the PN  prescription procedure met the clinical guidelines, the concentrations of glucose and 
protein were within the guidelines, but the vitamins and trace elements were, in 24% of  patients, 
either nonexistent or inadequate for the patients’ needs (Nardo et al., 2008). This same study found 
that 62% of the 200 studied patients were overfed while 14% were underfed. The authors of this 
study suggest that potential complications can be prevented by promoting the implementation of 
NSTs in hospitals.  
 In a study similar to the one described above, the neonatal team leaders in 296 French 
neonatal departments were queried using a closed-ended questionnaire as to their PN objectives 
for VLBW. This survey compared these objectives with the department’s daily practices. The 
authors of the study reported a 58% response rate (172 out of 296 NICUs). Ninety-three out of 
172 NICUs provided PN to VLBW, and 90 questionnaires were analyzed. Regarding the 
departments, PN objectives for VLBW, 49%, 40%, and 11% of the NICUs initiated amino-acids 
on day one, day two, and day three respectively. The amino-acid dosage used by 47%, 49%, and 
4% were 0.5, 1, ad 1.5 g/kg per day respectively.  Seventy-eight percent of the NICUs initiated 
lipids after the third day of life. Similarly, 78% of the units used 0.5g/kg/day of lipids to initiate 
PN treatment. When asked about the congruency between nutritional protocol and daily practice, 
56% of the participants noted that theoretical intakes were applied in all cases, while 22% of the 
interviewees responded that theoretical intakes were applied in 75% of cases. Respondents noted 
that the discrepancy between protocol and practice was mainly due to issues related to the patients’ 
disease, venous access, and requests from the prescribers. The authors further noted that, given 
the numerous publications on nutritional guidelines for PN administration in neonates and preterm 
infants, further training was required (Lapillonne, Fellous, Mokthari, & Kermorvant-Duchemin, 
2009).    
Another recent report conducted an analysis of the error rate at a large pediatric facility 
after it had put in place an electronic system to order, transcribe, compound and administer the 
entire PN process (MacKay, Anderson, Boehme, Cash, & Zobell, 2016). The hospital’s electronic 
system was built to comply with a national advisory group’s recommendations and the ASPEN 
guidelines for ordering, transcribing, compounding, and administering PN.  The authors reported 
that the error rate in their hospital was 0.27% as compared to the national average error rate of 
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1.6%. Such quality improvements in the entire PN process can reduce errors, improve health 
outcomes for neonates and preterm infants, and reduce PN associated costs as infants recover 
more quickly, and, therefore, the length of their hospital stay is reduced.  
In Ireland, a study conducted on the appropriate use of PN in an acute adult hospital found 
that 82 percent of PN prescriptions were appropriate while five percent were inappropriate, and 
13 percent were appropriate but avoidable (Smyth, Neary, Power, Feehan, & Duggan, 2013).  A 
case report on quality improvement over a ten-year period at the Hospital of the University of 
Pennsylvania found 15 opportunities for improvement at the baseline in prescribing, reviewing, 
compounding, preparing, administering, monitoring, reassessing, and documenting. Thirteen gaps 
were corrected so that the practices met the ASPEN guidelines and recommendations. The authors 
identified that accomplishing a “safe PN process may require a cultural shift, resources, education, 
and ongoing work” (Hudson & Boullata, 2014, p. 384).  
2.6 PN practices in developing countries  
While the literature on PN practices in the developed world is thorough, this is not the case 
for developing countries. In a recent report on the adherence to PN guidelines in an adult hospital 
in India, it was found that 0.24% of the patients received PN treatment and 0.18% of them received 
PN treatment for at least three consecutive days. Fifty percent of the patients initiated PN due to 
major gastrointestinal surgery and 26% due to intolerance to enteral nutrition. Regarding the 
venous access site used to deliver PN, 64% of patients received PN through a peripheral vein, and 
25% of patients received PN via a central venous line. Finally, the authors concluded that the 
appropriateness of PN indications and venous access sites to deliver PN needs to be reviewed. 
(Ramakrishnan, Shankar, Lakshmi Ranganathan, Bharadwaj, & Venkataraman, 2016)  
Another study conducted in India in the 1980s researched PN use in Indian NICUs and 
found that it was very difficult for NICU units to follow guidelines due to the unavailability of 
optimum amino acids, as well as an overall lack of funds. In this study, the physicians themselves 
compounded and delivered the PN formulations, and were not able to conduct the preparation 
under sterile conditions due to the lack of laminar flow hoods. They also concluded that sepsis 
was the most important complication seen in patients, which had an incidence of 52% (Chaudhari 
& Vaidya, 1988).  In a follow-up study to the above-described study, the neonatal leaders in the 
Indian neonatal department reviewed their PN practices. The authors of the study reported that 
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complications associated with PN were reduced by providing additional training to the healthcare 
personnel, compounding PN under a laminar flow hood, improving monitoring protocols, and 
supplying suitable intravenous equipment. Moreover, they updated their practices related to dose 
recommendations for amino acids and lipids in ELBW infants (Chaudhari & Kadam, 2006).   
In 2013, a randomized controlled trial study was conducted in India evaluating the effects 
of aggressive parenteral nutrition (APN) on nitrogen retention in VLBW and ELBW infants. This 
study found greater nitrogen retention in the APN group compared to the standard parenteral 
nutrition (SPN) group on day four and seven of the treatment. The time to regain body weight in 
the APN group was less than in the SPN group, 9.5 and 11.5 days respectively. Moreover, the 
average APN patient hospital stay was less than the SPN patient hospital stay. The authors of the 
study suggested that more research about safe PN practices in developing countries is needed. 
Finally, they concluded that APN is safe and feasible in India (Tagare, Walawalkar, & Vaidya, 
2013).  
 In the same year of the previous study, a retrospective cohort study on the appropriateness 
of PN indication in an adult patients’ hospital was conducted in Singapore. This study was 
compared with the previous audit cohort study completed in the same hospital in 2001. The 
authors found that the appropriateness of PN administration was greater than indicated during the 
previous study; this improvement was due to the availability of an NST and increased awareness 
among staff (Chuah et al., 2013).  
 In 2000 in South Africa, a study was conducted evaluating the efficacy of the “Standard 
All-in-One Bag of PN” in a neonatology surgery centre. This study reported that this method 
would be an effective nutrition solution for developing countries if they do not have an NST, 
pharmacy unit, or knowledgeable staff to prepare PN. Because the formulation is prepared in a 
specialized centre and supplied within 48 hours to facilities that request it, this formulation is not 
subject to many of the risks associated with in-hospital PN preparation (Chowdhary, Chitnis, 
Choudhary, Gossen, & Lazarus, 2000).  However, another study carried out in Egypt found that 
another method to improve PN practices in developing countries is education. In 2012, this study 
found that satisfactory knowledge about PN procedures improved from 10% to 90% after 
education was implemented. In addition, the practice of PN administration and monitoring for 
potential complications associated with PN was enhanced after a comprehensive guidelines 
program was provided to NICU nurses (Al-Rafay & Al-Sharkawy, 2012).  
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Finally, an interesting study on the evaluation of PN practices was conducted in Kuwait 
in 2016 where the researchers explored PN practices in seven hospitals (adult, pediatric, and 
neonate hospitals). Through interviews, this study found that there were no NST units at any 
hospital participating in the study: instead, physicians, pharmacists, dietitians, and nurses were 
involved in PN therapy. Order forms were handwritten, and all PN formulations were made 
according to the patient’s needs. Quality audits were performed in all the hospitals, and PN 
guidelines or protocols were developed in six of the seven NICUs (Katoue, Al-Taweel, Matar, & 
Kombian, 2016).  
2.6.1 Conclusions  
 Around the world, there are still significant inconsistencies in the ordering, transcribing, 
compounding, and administering of PN to neonates and preterm infants. As this literature review 
has demonstrated, there are a host of errors that can compromise the process. Even with a strong 
system and clinical guidelines in place, there are irregularities in the rate of delivery, inadequate 
ingredients, and over and underfeeding. This research outlines the rationale, objectives, and 
methodology which will be undertaken to study PN practices in NICUs in Quito, Ecuador. These 
practices have not been previously described. This research will also provide an opportunity to 
develop a baseline manuscript of hospitals’ practices to help them improve the outcomes for these 
fragile patients because “it is difficult to invite change if current practice is unknown” (Kuzma-
O’Reilly, 2003, p. e462).   
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3. PARENTERAL NUTRITION PRACTICES IN FOUR PUBLIC HOSPITALS IN 
QUITO: SURVEY RESULTS 
3.1 Objectives:  
Describe the current PN practices and resources 
Identify if current PN practices are standardized   
3.2 Methods:  
3.2.1 Methodology  
  A qualitative grounded-theory methodology was used in this study. According to Creswell 
(2006), the grounded-theory approach helps to explain a practice or provide a framework for 
future research based on the views of participants, primarily through interviews (Creswell, 2006). 
An in-depth survey was administered to participating health care personnel between November 
2017 and February 2018 to describe the current PN practices and resources in the four public 
hospitals in Quito and to identify if the practices were aligned with published guidelines: ASPEN, 
ESPGHAN & ESPEN, British Association of Perinatal Medicine, and Practice of Parenteral 
Nutrition in VLBW and ELBW Infants. Through their representatives in the “Eugenio Espejo 
hospital of Specialities Ethics Committee,” the Ecuadorian Ministry of Health Ethics Committee 
approved this project for all participating hospitals:  Hospital Gineco-Obstetrico Nueva Aurora 
(HGONA), Hospital Gineco-Obstetrico Isidro Ayora (HGOIA), Hospital General Docente de 
Calderon (HGDC), and Hospital General Enrique Garces (HGEG). In addition, the University of 
Saskatchewan Ethics Committee approved this research project.  
3.2.2 Participants:  
 To obtain the most accurate information, four health care professionals from the NICUs 
at HGOIA and HGDC, three from HGEG, and five from HGONA participated in this study. A 
recruitment meeting was held with each leader of the four NICUs with the aim of obtaining a list 
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of names of professionals nominated to participate in this survey. These professionals were 
selected because they were considered the most knowledgeable personnel in relation to the 
hospital’s PN procedures. As such, the interview participants included physicians, nurses, 
pharmacists, and a dietitian. A total of sixteen professionals were asked to and consented to 
participate in the interviews.    
3.2.3 Survey  
The open-ended and closed-ended questionnaire was developed based on a literature 
review. The questionnaire was content validated by a pediatrician and a neonatologist at HGONA 
who did not participate in the study, and a pediatric surgeon, two dietitians and members of the 
research team.  This questionnaire consisted of seven sections. The first section consisted of 12 
short-answer questions which inquired about the number of hospital and neonatal beds, the 
number of patients admitted yearly and what percentage of these admissions are neonates below 
2.5 kg, and the profession of the interviewee, their role, their years of experience, and their shift 
work. The second section inquired about the number of neonatal beds in each unit, including basic, 
intermediate, and intensive care units. This section also asked about the presence of laminar flow 
hoods used to compound PN.  
   The third section described the patient population of the neonatology area. The 
questionnaire inquired about the incidence of neonates and VLBW neonates on PN and the 
common reasons for initiating PN. Section four asked about the presence of an NST, its members, 
and their roles. Section five gathered information about parenteral nutrition design. The 
questionnaire included 27 questions which inquired about the methods used to prescribe, 
calculate, prepare, package, label, store, and administer PN; the clinical guidelines used to manage 
PN; the regimen of PN that is used most frequently; the doses of amino acids, dextrose, and lipids 
used to initiate PN; and the most frequent venous access line used to administer PN. Section six 
asked about the frequency of biochemical and anthropometric assessments of patients before 
beginning PN and after PN has been initiated.  Section seven gathered data about the guidelines 
used to manage complications. The last section inquired about the health care professional 
responsible for discontinuing PN, the reasons for stopping this treatment, and the guidelines or 
protocols used to guide this aspect of the PN treatment (See Appendix A).   
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This survey contained eleven open-ended questions which allowed participants to fully 
explain potential changes, issues, or limitations during PN administration. Furthermore, these 
questions let them explain in detail what precautions are taken to avoid potential complications 
and errors. The open-ended questions included:  
1. What are the barriers to having a functional NST?  
2. Have there been any changes in the past five years in regards to the PN design?  What?  
3. Have you faced any difficulties, problems, or challenges during the period that you have 
been involved in PN administration?  What?  
3.2.4 Data Collection  
All interviews were carried out individually and face-to-face except for one interview which 
was performed by phone. All interviews were conducted privately at an agreed upon location. 
Prior to the start of the interview, a brief explanation of the project was delivered, and a consent 
form signature was obtained for participation in the study and the creation of an audio-record of 
the conversation. All participants agreed to be interviewed and audio recorded.  Questions were 
clarified if the participant required additional explanation. Then, all interviews were transcribed 
and translated from Spanish to English.   
3.2.5 Addressing credibility in qualitative research  
Some of the strategies suggested to assess trustworthiness in qualitative research are 
triangulation which is the use of multiple and different sources to corroborate evidence, peer 
review, in member checking which uses the participant’s point of view of the confirmability of 
the findings, and rich description of the participants and environment (Creswell, 2006). In this 
study, the strategies used to assess the credibility of the findings included a detailed description 
of the participants and resources from the NICUs and triangulation.  The sources used to 
corroborate the evidence include a medical record review and published PN clinical guidelines.  
3.2.6 Data Analysis  
In-depth interviews were audio recorded, transcribed, and translated verbatim. Closed-ended 
questions were presented as frequencies with their respective percentage and means with standard 
deviation. Open-ended questions were analyzed for content; thus, answers were coded and then a 
list of potential themes was created. Those themes represented participants’ opinions regarding 
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parenteral nutrition practices during delivery of PN in their NICUs.  All statistical analyses were 
performed using IBM SPSS Statistics 25 for Windows Server 2012 R2.  
3.3 My experience during the study of parenteral nutrition practices in four hospitals in Quito- 
Ecuador   
How are parenteral nutrition practices being developed in public hospitals in Quito, my 
home city? This question came to mind after working as a junior practitioner in one of the pediatric 
hospitals in Quito.  Upon receiving a participation interest letter from one of the participant 
hospitals and the approval of my research proposal, the journey to find the answers to my inquiries 
had begun. My next step was to develop the main purpose of the study, which is to gain in-depth 
knowledge about PN practices and to help improve these practices, if necessary, for the hospitals 
participating in this project. At the end of several meetings and conversations with the 
representatives of the Academic Department and NICU in each hospital, three more hospitals 
expressed their interest in participating in this study and thus their willingness to open their doors 
to the opportunity to change and improve their parenteral nutrition practices. It is important to 
note that the study was originally proposed as a six-hospital participant project; however, two of 
these hospitals declined to participate due to the ongoing restructuring of their NICU’s procedures. 
They expressed that the potential data collected will not accurately reflect their current practices.  
   With four participation interest letters issued by the four participating hospitals and a 
detailed research protocol proposal, the Ecuadorian Ministry of Health Ethics Committee through 
their representatives at the “Eugenio Espejo Hospital of Specialities Ethics Committee” issued a 
letter of approval on November 7, 2017. This letter approved the execution of this project in the 
four participating hospitals within the time frame of one calendar year. This approval letter 
guaranteed the researcher both logistic cooperation and the provision of the information required 
for this study by each hospital and its health care personnel.  
Data collection was initiated immediately after obtaining the ethics approval letter from 
the Ecuadorian Ministry of Health Ethics Committee. The first hospital visited was the HGONA, 
our research partner in Ecuador. Ninety-eight neonate medical records were reviewed, and four 
health care personnel involved in TPN treatment were interviewed at this institution. Next, face-
to-face interviews were conducted with all health care personnel at HGDC, HGEG, and HGOIA, 
except one interview with the dietitian which was performed via phone. Lastly, for approximately 
two months, 104 medical records were reviewed at HGOIA. Representatives and personnel at 
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these four hospitals provided all the support and transparency required to execute this project at 
their institutions.  
 The data collection was completed without major difficulty; however, there were three notable 
issues faced during this process. First, obtaining the participation letter from each hospital was a 
long and bureaucratic process. This is because, during the authorization process, directors and 
personnel at the NICUs held numerous meetings and discussions before finally granting their 
approval. Second, the long distance between hospitals, around one to two hours, posed a logistical 
challenge. This means that a significant amount of this study’s time was invested in transportation. 
Finally, because the medical records were not digital and the majority were handwritten, 
interpreting the records and locating missing pages was time-consuming.  
At its completion, this project and its execution provided an enriching research experience 
and a path to pursue my professional and academic goals. This project provided enormous 
satisfaction in that it has allowed me to contribute, if slightly, to the welfare of Ecuadorian neonate 
patients at the NICUs in the public hospitals in Quito-Ecuador. “The likely solutions for nutrition 
problems lie less in unlocking biological pathways than in creating…environments that can 
deliver correct balances” (Lang, 2005, p. 731).  
 3.4 Results  
3.4.1 Closed-ended questions results  
Sixteen health personnel at four NICUs in public hospitals in Quito were proposed by their 
respective supervisors. A 100% (16 out of 16) rate of participation was obtained since all proposed 
professionals accepted the interview invitation. After analyzing the hospitals’ official records, we 
determined that the mean number of neonatal beds was 32 (SD 18.2). HGONA has 40 neonatal 
beds, HGOIA has 55, HGDC has 15, and HGEG has 21. Furthermore, by analyzing the available 
information from HGONA and HGOIA’s NICUs, we discovered that there were 257 and 216 
neonates receiving PN annually respectively. Unfortunately, the official records of the patients 
receiving PN in the remaining two NICUs were not available. The description of the NICUs and 
the annual number of neonates on PN are showed in Table 3.1.   
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 Table 3.1 Description of the neonatal units and demographic population in four public neonatal units in Quito  
  Mean  SD  Total  
Number of hospitals  4    4  
Number of NICUs  4    4  
Participants interviewed  16    16  
Hospital beds*  216  80.5  864  
Neonatal beds*  32  18.2  131  
Places of basic care**  9  15.5  36  
Places of intermediate care**  16  6.8  64  
Places of intensive care**  10  2.3  40  
Neonates receiving PN annually***  236  28.9  514  
                                PN=parenteral nutrition   NICUs= neonatal intensive care units  
                               *Information obtained from official records  
                               ** Information obtained from survey answers  
                               *** Information obtained from official records (HGONA and HGOIA)  
  
  
3.4.1.1 Demographic characteristics of the participants  
Five participants (31%) were pediatricians, and four were nurses (25%). One dietitian 
(6%) participated in this survey. The years of experience of the participants in their health care 
area ranged from five to eleven years. The demographic characteristics and roles of the 
interviewees (n=16) are shown in Table 3.2.  
  
Table 3.2 NICUs’ personnel professional background and role description  
Academic degree  n (%)   Experience 
mean  
(years)  
  
Experience 
SD   
Shiftwork 
mean 
(hours)  
Shiftwork 
SD  
Role  
Neonatologist  3 (19)  11.5  8.3  24  5.1  Responsible of the shift  
Pediatrician  5 (31)  7.6  5.1  23.6  3.5  Responsible of the shift  
Pharmaceutical 
biochemist  
3 (19)  10.7  8.9  8.5  0.5  • Compound PN  
and medication control  
(n=2)  
• Pharmacy leader (n=1)  
Nurse  4 (25)  10.6  14.2  11.7  1.2  Provide direct care of the 
patient  
Nutritionist  1 (6)  5    6    PN supervisor and head of milk 
bank in the hospital  
SD= standard deviation   PN= parenteral nutrition       Nutritionist (Ecuadorian degree) = dietitian degree  
3.4.1.2 Parenteral nutrition practices  
Closed-ended questions and their respective responses are shown in Table 3.3.  
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Table 3.3 Parenteral nutrition practices in the NICUs  
Question  Answer  n (%)  
Does this hospital have a laminar flow hood to prepare PN? *  Yes  
No  
Do not know  
5 (31)  
8 (50)  
3 (19)  
Is there a nutrition support team (multidisciplinary team of 
nutritional support) in this hospital? *  
Yes  
No  
Do not know  
3 (19)  
12 (75)  
1 (6)  
Who is the health professional that prepares parenteral nutrition 
formulations? *  
Pharmacist  
Nurse  
Do not know  
11 (69)  
3 (19)  
2 (12)  
Do you use paper orders or digital orders?  Paper orders  16 (100)  
Do you write this order manually or digitally? *  
  
Digital  
Manual  
Manual/Digital  
12 (75)  
2 (12.5)  
2 (12.5)  
Where is PN prepared? *                                                                    Pharmacy  
NICU  
Operating theatre  
PN unit  
Do not know  
3 (19)  
7 (44)  
2 (12)  
1 (6)  
3 (19)  
Do you use any PN calculation software (ABACUS, Baxter) to 
calculate PN? *  
Excel conversion 
spreadsheet  
Manual  
Excel conversion  
spreadsheet/manual  
14 (88)  
  
1 (6)  
1 (6)  
Are manual or automated compounding devices used (ACDs) to 
prepare PN formulations? *  
Manual  
Do not know  
10 (62)  
6 (38)  
How many days does the PN unit work?   Operate daily  16 (100)  
If you prepare PN bags for days when the PN unit is not 
operating, please explain how you store them? *  
Not store PN 
Kept in 
refrigeration  
13 (81)  
3 (19)  
What kind of PN regimen do you use frequently?   Always individual  
Always standard  
(first 24h of life)  
16 (100)  
4 (25)  
Are you using a published clinic guideline to manage the PN? *  
  
Yes  
No  
Do not know  
6 (38)  
9 (56)  
1 (6)  
Do you use an unpublished PN guideline to manage PN? *  Yes  
No  
Do not know  
7 (44)  
7 (44)  
2 (12.5)  
Who makes the decision to cease PN?   Physician  16 (100)  
            PN= parenteral nutrition  
         * Response inconsistent between all members in the same NICU  
  
  When asked whether there is a laminar flow hood to prepare PN in their hospital, eight 
participants (50%) noted that their institution did not have one while five interviewees (31%) 
stated that their institutions have laminar flow hoods.  The response of the four interviewees at 
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one NICU was inconsistent. One respondent noted that the unit used a laminar flow hood, two of 
the respondents said that there was no laminar flow hood in the NICU, and the fourth respondent 
did not know whether or not the unit used a laminar flow hood. Twelve participants (75%) denied 
the existence of NSTs in their institutions. In one of the NICUs, half of its participants asserted 
that there is an NST while the other half of their participants denied the existence of this team. In 
the other NICU that presented the same issue, one of the interviewees noted that they have an 
official NST team while the rest of their colleagues denied that their hospital had an NST team. 
Three participants (19%) of the participants opined that their NICUs had non-official NSTs. These 
respondents described the members of the non-official team as including physicians, nurses, 
pediatrician-nutritionist, pharmacists, and dietitian. Another participant noted that a physician, 
nurse, and pharmacist were members of this team while the last participant described a physician 
and dietitian as the team’s members.  
Twelve participants (75%) agreed that PN orders were written digitally. In one of the 
NICUs, there was a discrepancy in the responses: half of the interviewees declared that they write 
the order forms manually while the other half said that orders are written both manually and 
digitally. Seven participants (44%) noted that PN is compounded in the NICU. In two of the 
NICUs, there was inconsistency in the participants’ responses. In one of the NICUs, one 
participant noted that PN is compounded in the pharmacy unit while another interviewee said it 
was compounded in the PN unit. In another NICU, half of its members noted that PN is 
compounded in the pharmacy unit while the other half said that it was compounded in the 
operating theatre.   
Regarding the use of calculation software, fourteen interviewees (88%) noted that they use 
an Excel conversion spreadsheet make PN calculations. The automate order entry helps the 
professionals with maximum defaults for electrolytes and maximum osmolarity of dextrose 
solution. In one of the NICUs, there was a discrepancy between participants’ answers. While two 
interviewees said their unit uses an Excel conversion spreadsheet, other participant responded that 
the unit uses manual calculations, and another said the calculations are determined both manually 
and using an Excel conversion spreadsheet.  Thirteen participants (81%) denied storing PN 
formulations, and three participants (19%) asserted that PN is kept in refrigeration (-4°C). In one 
of the NICUs, while half of the interviewees noted that their unit did not store PN, the other half 
said that they did. All interviewees (100%) noted that their units prepared PN formulations daily. 
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Six interviewees (38%) asserted that they use a published guideline to manage PN treatment and 
seven participants (44%) noted that they use an unpublished guideline, such as consensus, the 
protocol of their NICUs, or the Ecuadorian Ministry of Health protocol. Finally, eleven 
participants (69%) noted that the pharmacist is the professional who compounds PN formulations 
and three interviewees (19%) noted that a nurse prepares the formulations.  
3.4.1.3 Reasons for beginning and ceasing PN  
Among the frequently cited reasons for neonates receiving PN treatment are a weight 
below 1.5 kg (88%), necrotizing enterocolitis (75%), and digestive intolerance (63%). 
Furthermore, the most common reason to cease PN was the patient commencing an oral diet or 
enteral feeds (81%) followed by when patients’ requirements are met (44%) (Table 3.4).  
  
Table 3.4 Parenteral nutrition reasons for beginning and ceasing PN  
Reasons  n (%)  
Reasons for beginning PN    
   Neonates <1kg & <1.5kg  
   Necrotizing enterocolitis         
   Digestive intolerance                
   Risk of necrotizing enterocolitis       
   Gestational age                    
   GI malformations   
   Short intestine  
   Malabsorption syndrome  
   Chylous leak  
   Esophageal rupture                       
  
  
14 (88)  
12 (75)  
10 (63)  
9 (56)  
10 (63)  
8 (50)  
7 (44)  
7 (44)  
4(31)  
4 (31)  
Reasons for ceasing PN  
   Patients’ requirements are met  
   Patient commence on oral diet or enteral feeds  
   Referring medical team makes the decision to cease PN  
   When complications appear  
  
  
7(44)  
13 (81)  
3 (19)  
2 (12)  
                                  PN= parenteral nutrition      GI= gastrointestinal  
3.4.1.4 Parenteral nutrition order forms  
All four NICUs have developed their own Excel conversion spreadsheets which help them 
make accurate calculations. This method includes dose limit and electronic computations. After 
designing the PN treatments using Excel, legibly printed orders are obtained. Paper orders at the 
four NICUs typically contain patient information; PN treatment information such as components, 
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dose, and amount to be delivered; glucose infusion rate (GIR); calories provided; osmolarity; 
nonprotein and protein ratio; flux of drip; and the venous access site. Finally, this order form is 
signed by the professional who prescribed the PN (Appendix B). The Excel conversion 
spreadsheet format (not identical spreadsheet) used by all NICUs is shown in Figure 3.1.   
 
                  Figure 3.1 Excel conversion spreadsheet format  
  
3.4.1.5 Monitoring patients receiving PN treatment   
Thirteen interviewees (81%) asserted that they perform a biochemistry assessment before 
beginning PN administration in neonate patients in their units while two participants noted that 
they did not (Table 3.5).  
  
Table 3.5 Biochemistry assessment before PN administration  
Biochemistry assessment  n (%)  
Yes  
No  
Do not know  
13 (81)  
2 (13)  
1 (6)  
  
  Nine participants (56%) described that complete blood count (CBC) is always performed 
before beginning PN in the patient. Two participants noted that the CBC is evaluated occasionally. 
Eleven interviewees (69%) stated that blood glucose levels are always assessed before beginning 
PN treatment in the neonate patient, while two individuals (13%) said that they did not know if 
blood glucose levels were always measured before the initiation of PN. Electrolytes measurement 
was the test most frequently assessed. Twelve participants (75%) noted that they always test the 
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electrolytes before beginning PN. The frequency of assessment of other tests, such as hepatic 
enzymes, total protein and albumin, urea and creatinine, vitamins and minerals, and cholesterol 
and triglycerides are shown in Table 3.6.  
  
Table 3.6 Frequency of biochemistry assessment before PN administration  
Biochemistry assessment before PN 
administration  
Always 
n (%)  
Mostly n 
(%)  
Sometimes 
n (%)  
Never 
n (%)  
Do not 
n (%)  
Frequency of CBC assessment  
Frequency of blood glucose level assessment  
Frequency of electrolytes assessment  
Frequency of hepatic enzymes assessment  
Frequency of total protein/ albumin assessment  
Frequency of urea/creatinine assessment  
Frequency of vitamins and minerals assessment  
Frequency of cholesterol/triglycerides 
assessment  
9 (56)  
11 (69)  
12 (75)  
9 (56)  
9 (56)  
8 (50)  
2 (13)  
7 (44)  
1 (6)  
0 (0)  
0 (0)  
1 (6)  
2 (13)  
1 (6)  
0 (0)  
3 (19)  
2 (13)  
0 (0)  
0 (0)  
1 (6)  
0 (0)  
3 (19)  
2 (13)  
0 (0)  
0 (0)  
0 (0)  
0 (0)  
0 (0)  
0 (0)  
0 (0)  
7 (44)  
2 (13)  
1 (6)  
2 (13)  
1 (6)  
2 (13)  
2 (13)  
1 (6)  
2 (13)  
1 (6)  
CBC= complete blood count      PN= parenteral nutrition  
Five (31%) and six interviewees (38%) interviewees stated fluid balance and blood 
glucose level respectively are assessed every 12 hours in patients on PN treatment; however, there 
is a disperse range of frequency of assessment mentioned by the participants (Table 3.7).  
Table 3.7 Assessment of fluid balance and blood glucose level in patients on PN  
Assessment in patients on PN  n (%)  
Fluid balance  
At least once a day  
Every 12 or 6 hours  
Every 12 hours  
Every 8 hours  
Every 12 hours or once a day  
Every 8 or 12 hours  
Every 3 or 6 or 12 hours  
Do not know  
  
Blood glucose level  
At least once a day  
Every 3 or 6 or 12 hours  
Every 12 hours  
Every 8 hours  
Every 8 or 12 hours  
Every 6 hours  
Every 6 or 12 hours or once a day  
Do not know  
  
2 (13)  
1 (6)  
5 (31)  
2 (13)  
1 (6)  
1 (6)  
1 (6)  
3 (19)  
  
  
1 (6)  
1 (6)  
6 (38)  
2 (13)  
1 (6)  
1 (6)  
1 (6)  
3 (19)  
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3.4.1.6 Prescribed Macronutrients  
Regarding amino-acid prescription, eleven participants noted that a range of amino-acids 
was provided from 1 to 4 g/kg per day in preterm neonates. Similarly, participants asserted that 
the appropriate range for this macronutrient in term neonates is 1 to 3.5g/kg per day.   A range of 
glucose infusion rates, from 3.5 to 8 mg/kg per minute, is used to initiate PN in both preterm and 
term neonates according to the participants’ responses. Finally, nine interviewees (56%) noted 
that they use a 20% lipid emulsion and that the dose range used is from 0.5 to 4 g/kg per day in 
preterm neonates and from 1 to 3g/kg per day in term neonates (Table 3.8).  
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Table 3.8 Prescribed macronutrients  
 Prescribed macronutrients  Preterm 
neonates 
n (%)  
Term  
neonates 
n (%)  
Amino-acids (g/kg per day)  
       1.5 to 3.5  
       1  
       2 to 2.5  
       2  
2 to 3  
       2.5  
       3  
3 to 3.5  
       3.5  
       3.5 to 4  
       4  
       1 to 3  
       Do not know     
       Do not use         
  
1 (6)  
1 (6)  
1 (6)  
1 (6)  
1 (6)  
1 (6)  
1 (6)  
1 (6)  
1 (6)  
1 (6)  
1 (6)  
  
5 (32)  
  
  
  
  
  
2 (12)  
  
  
2 (12)  
1 (6)  
2 (12)  
  
  
1 (6)  
5 (32)  
3 (19)  
Glucose Infusion rate (mg/kg per min)  
      3.5 to 8  
4 to 6  
5 to 7  
4 to 8  
      6  
5 to 6  
      Do not know     
      Did not mention   
  
1 (6)  
4 (25)  
1 (6)  
1 (6)  
2 (13)  
1 (6)  
6 (38)  
  
1 (6)  
5 (32)  
  
  
1 (6)  
1 (6)  
6 (38  
2 (12)  
Type of lipid emulsion   
      10%  
      20%  
      10% & 20%  
      Do not know  
  
3 (19)  
9 (56)  
1 (6)  
3 (19)  
  
3 (19)  
9 (56)  
1 (6)  
3 (19)  
Lipid (g/kg per day)  
       0.5 to 3        
1  
1 to 2  
       1.5 to 2        
2 to 2.5        2  
2 to 3  
       3   
3 to 4  
       Do not know     
       Do not use it  
       Did not mention  
  
1 (6)  
2 (13)  
1 (6)  
1 (6)  
1 (6)  
2 (13)  
1 (6)  
1 (6)  
1 (6)  
5 (32)  
  
  
2 (13)  
  
1 (6)  
1 (6)  
3 (19)  
1 (6)  
  
  
5 (31)  
1 (6)  
2 (13)  
  
As shown in Table 3.8, there is no consensus between health professionals with respect to 
the range of amino-acid dosages used to begin PN in preterm and term neonates. A similar 
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situation is observed when participants describe the range of glucose infusion rates and lipid 
dosages used to initiate PN in neonates. Raw data of this survey is shown in Appendix C.  
3.4.2 Open-ended questions results  
All open-ended question answers were listed by question and profession to provide a more 
nuanced appreciation and comparison. Nine essential, nonredundant themes arose from this data.  
Each theme is listed and described using direct quotes from the individual interviewed.  
Theme 1: Physical and service changes in the NICUs  
Thirteen of sixteen interviewees expressed that there have been changes regarding the 
number of beds /incubators or places of care in their units and the availability of laminar flow 
hoods to prepare PN. There were two specific areas of change. One area of change is alterations 
to the hospital’s and unit’s physical space. There have been increased numbers of beds or places 
of care, units, and changes in the infrastructure of their NICUs. Additionally, one institution 
acquired a laminar flow hood to prepare PN exclusively.    
"We implemented the Canadian standards of care accreditation to improve our service. There was a remodelling 
process of the Intensive, Intermediate, and Basic Care Units".  
  
Two physicians, one at the HGOIA and one at the HGEG, and one pharmacist at the 
HGDC, denied changes in their institutions.   
The second area of change involves changes in the services provided. Interviewees noted 
that a cholestasis protocol had been introduced in one NICU, and the majority of the interviewees 
agreed that there had been an increase in the demand for services and, for that reason, an increase 
in the number of patients admitted in their NICUs.   
"Many changes have occurred because this hospital has only been operating for three years. Every year there are 
great changes in infrastructure and the protocols implemented. This is a new hospital, so it changes constantly."  
  
Theme 2: Availability is one change regards to the number of patients on PN and the reasons to 
begin PN.  
Ten of sixteen interviewees expressed that there have been changes to the number of 
patients receiving PN in their units and the reasons used to initiate PN. There were changes in the 
availability of PN support in their NICUs for all neonates below 1500g or premature neonates. 
Interviewees also noted increased availability of early PN support, specifically the early delivery 
of lipids and amino-acids during the first 24 to 48 hours of life. As a result of the improved 
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availability of PN support, there has been an increase in the number of patients receiving PN in 
their respective NICUs. Finally, an Excel spreadsheet format to help health personnel make PN 
calculations accurately has been introduced.   
"Yes, there have been changes. Previously TPN was delivered as it was believed necessary. Today we have 
established that bellow 1500g, we initiate TPN. Also, there has been a change regarding initiating TPN as early as 
possible on the first day of life. We have established a new protocol to treat cholestasis whereby we initiate TPN in 
cycles".  
Two physicians at the HGEG, one pharmacist at the HGDC, one nurse at the HGEG, one nurse at 
the HGOIA, and a dietitian at the HGONA denied changes.  
  
Theme 3: Shortages and PN training are the barriers to developing a functional Nutritional 
Support Team from humble beginnings  
Twelve of sixteen interviewees expressed that there are two main barriers to developing a 
functional NST in their institutions. One of the limitations is the shortage of some elements needed 
to implement this team, including personnel, funding, and physical space. In addition, there are 
PN training barriers. Interviewees noted that there is a lack of familiarity with NSTs and their role 
in neonatal nutrition. Also, the respondents noted that an NST would require specifically trained 
personnel who exclusively participate in the nutritional support of neonate patients.  
"I think the main limitation is the hospital’s budget because an exclusive team should provide TPN. We, as 
pharmacists, know the necessity of this team and have tried to adapt the way we work. There should be an exclusive 
budget for a TPN pharmacist because we are contracted to work with a unit and TPN is an additional task that we 
must perform. We need more exclusive personnel to prepare therapies including physicians and nutritionists who 
work exclusively with nutritional therapy".  
  
Three physicians, one at the HGONA, one at the HGOIA and one at the HGDC, and a nurse at 
the HGONA did not answer this question.  
  
Theme 4. Compounding and Calculation changes in the PN treatment  
Ten of the sixteen interviewees expressed that there are two main areas of change in their 
institutions. One area of change is in the PN compounding process. Most interviewees agreed that 
new personnel were involved in PN treatment. Initially, pharmacists did not participate in the PN 
process, but now they are an important part of the PN treatment. Also, respondents referred to 
changes in the roles of nurses and pharmacists. They noted that previously nurses compounded 
PN; however, currently, pharmacy personnel are responsible for compounding and preparing PN.  
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Additional reported changes included the acquisition of laminar flow hoods and the introduction 
of software to compound and calculate PN.  
"Previously, the nurses prepared TPN. They were trained to do so. In this hospital, we did not provide a TPN but 
partial PN. Thus, we avoided administering lipids because there was a major risk of infection in the patients. TPN 
was restricted for that reason. Since there are a laminar flow hood and a better-organized pharmacy unit, we can 
use Total PN".   
  
Five physicians, two at the HGONA, two at the HGEG, and one at the HGDC, and a nurse at the 
HGEG denied changes in their units.  
Theme 5. Potential errors and measures to prevent them  
All participants expressed that there have been errors related to the prescription, 
submission, and transcription of PN orders. Other errors were found on PN labels. Some 
interviewees noted that label information did not match the prescription. There have been errors 
in the PN schedule, and on some occasions, the PN did not last until the time stated on the 
prescription. In some units, measures have been taken to prevent potential complications related 
to PN treatment. Interviewees noted that their units now double check the patient information and 
dose, use sterile protocols, take PN cultures, and perform visual inspections of the PN bags. At 
the HGOIA, personnel specified performing other measures such as gravimetric analysis and 
microbiological tests.  
"Sometimes the TPN prescription does not reach the pharmacy unit and is not prepared, which is inconvenient. When 
the TPN prescription does not reach the pharmacy unit, the TPN bag does not arrive (a missing TPN).  Prescriptions 
should arrive in the morning to be prepared.  When we receive TPN bags, we record their weight because we had an 
issue with TPN bags ending before their programmed time. We observe the appearance of the bags to verify that they 
are well sealed and do not have cracks. Also, we observe any extravasation in the patient. If the neonate does not 
require TPN or if we have concerns about the TPN quantity, we communicate with the physician"  
  
Theme 6: Calculating, compounding, and administrating changes in the parenteral nutrition 
design  
Thirteen of sixteen interviewees expressed that there are three main areas of change in 
their institutions. One area of change is in the PN calculation process. Mostly they agreed that 
new software was implemented to make PN calculations. Another area of change was to the PN 
compounding process; notably, changes to the pharmacists’ and nurses’ roles have occurred. 
Currently, the pharmacist compounds PN. Finally, there have been changes in the administration 
process. Participants noted that there has been earlier lipids administration. In addition, a higher 
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dose of macronutrients is currently used in PN administration. Finally, some respondents noted 
heparin disuse in their units.  
"We try to initiate PN with higher values because we previously initiated with low values, around 0.5, and we 
performed slow increases. Thus, we did not reach the basal values to supply the needs of the patient, at least the 
protein. As I told you, we initiated with 0.5 mg of amino acids and lipids, for two or three days. On the fifth day, we 
would increase to 1mg. It was a slow TPN process".  
  
One physician at the HGEG, and one pharmacist and a nutritionist at the HGONA denied changes 
in their units.  
  
Theme 7: Complication management depends on patient needs.  
In general, interviewees noted that if they observe complications related to PN, they 
discontinue its use. Nurses and pharmacists noted that they communicate these complications with 
the physician.  
Hyperglycemia and Hypoglycemia Management  
This was primarily addressed by physicians and nurses. They noted that if they observe 
hyperglycemia, they decrease or regulate the flux of PN or discontinue it until normal levels are 
restored. Interviewees noted that if they observe hypoglycemia in the patient, they increase or 
regulate the PN flux or discontinue its use.  
Cholestasis Management  
If cholestasis is observed in the patient receiving PN, physicians decrease the lipids and 
amino-acids, deliver the PN in cycles or discontinue the PN.  
“It depends. For example, in hyperglycemia, I decrease the flux of glucose or discontinue the TPN. For hypoglycemia, 
I pass a dextrose bolus and increase the contribution of glucose or discontinue the TPN. For cholestasis, we just 
provide amino acids in the TPN and provide lipids twice per week. For patients with sepsis, we do not discontinue 
the TPN.”  
  
Sepsis Management  
In the case of potential sepsis in patients receiving PN, physicians noted that they 
investigate all access to the patients. They perform a urine culture, stool culture, secretion culture, 
etc. The physicians’ opinions regarding their responses to complications related to PN were very 
similar. Nurses and pharmacists agreed that they report these issues to physicians.  
"If there is cholestasis, we stop the lipids. If there is sepsis, we investigate all access to the patient because TPN 
cannot cause this condition. For example, if the patient is in a mechanical ventilator and doing physiotherapy, that 
is probably how they were exposed to a microorganism. In the case of hyperglycemia or hypoglycemia and we suspect 
sepsis, we discontinue the TPN and provide the patient with adequate dextrose."  
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 Theme 8: Cholestasis and hyperbilirubinemia management has changed in the NICUs  
Only six participants expressed that there have been changes regarding the management 
of complications related to PN in their institutions. These participants expressed changes in the 
management of two specific complications. One of these complications is cholestasis. The 
respondents noted that a new cholestasis management protocol had been implemented in their 
units. Also, they noted that there had been an update to the criteria for the diagnosis of cholestasis. 
Finally, they mentioned that when a patient is diagnosed with cholestasis, they deliver a partial 
PN or deliver the PN in cycles to manage the complication. The other complication related to PN 
administration that was noted by interviewees was hyperbilirubinemia. Respondents asserted that 
new diagnostic charts were implemented in their NICUs. All of these changes were implemented 
in order to avoid complications in the neonate patient.  
"Now, during cholestasis evaluation, we do not only evaluate direct bilirubin, we evaluate GOT GPT GGT to begin 
to reduce the TPN infusion, give an alternate TPN cycle or use a medication to help us manage the condition.”  
  
Theme 9: Personnel, training, protocol, physical space, and resources are the challenges faced 
by the participants  
When asked about difficulties, problems, or challenges during the period that they have 
been involved in PN administration, all interviewees asserted that they had faced such challenges, 
except one physician at the HGEG who denied experiencing any problems during PN 
administration. Participants noted that they experienced difficulties related to the health care 
personnel involved in this treatment. They said that more specialized personnel are required to 
administer PN treatment in their units. Some of the interviewees said that in order to provide better 
quality PN treatment, an NST is needed in their unit.  
"Now, what is needed is a nutritional support group to work towards excellence in TPN administration, calculations, 
and compounding, of course. Currently, we have a pharmaceutical biochemist, physician, and nurse on the shift, but 
not an exclusive person to administer the TPN treatment. A nutritional support team should exist. If this is the optimal 
method, we should use it. If I am working in a third level hospital, there should be a multidisciplinary team".  
  
Also, they noted that more thorough and up-to-date training to address PN and PN 
complication management is needed to help unit personnel improve their skills.   
"I believe that we need to study cholestasis cases more closely to determine whether to immediately stop the lipids or 
whether we need to decrease them progressively. I mean we need more training in cholestasis management. Also, 
training about caring for patients who received TPN for the short and long-term."   
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In order to standardize the procedures related to PN treatment, interviewees suggested that the 
development of PN management protocols is required in their NICUs.  
"Despite that, we do not have a protocol, we have our methods well established for managing our patients. This is 
because we review the literature. We have no written protocol, but we have our management methods. It’s likely that 
developing a protocol will be a necessity. We need to record our methods because there are guidelines that we have 
reviewed and used in the unit".  
  
Participants also noted problems related to their NICUs’ physical space and resources. Some 
respondents declared they lack an appropriate physical space for PN treatment compounding. An 
additional challenge noted by interviewees was the need for a laminar flow hood to compound 
PN in order to provide patients PN that meets sterile standards.  
"We always have the ingredients to compound TPN formulations. We never have problems regarding the material 
provisions.  In order to meet the aseptic norms, it is necessary to have a laminar flow hood to prepare the TPN”.  
  
3.5 Discussion  
           PN is used to improve health outcomes of VLBW and ELBW infants by promoting their 
growth and development thereby improving their health and likelihood of survival. Our findings 
indicate that the lack of a formal and functional NST is common in the observed NICUs and that 
there is little participation from dietitians in PN treatment. The absence of nutritional professionals 
was clear as there was only a single dietitian working at one of the four NICUs in this study. Our 
results replicate the findings of Katoue et al.’s survey (2016) study in which they found that none 
of the seven participating NICUs in Kuwait had an active NST, and similarly, dietitians had little 
participation in PN treatment (Katoue et al., 2016). Likewise, Hill’s survey (2015) found that 
more than a half of South Africa’s NICUs had no official NST and 50 % of dietitians worked 
jointly with physicians to support nutrition decision making (Hill, 2015).  
   In NICUs where there is no formal NST, physicians had extensive involvement in PN 
treatment. Katoue et al. (2016) pointed out that physicians in non-NST NICUs performed several 
duties, including making PN clinical decisions, and ordering and ceasing PN treatment (Katoue 
et al., 2016). Even compounding and monitoring patients on PN treatment was performed by the 
chief resident in an NICU in India (Chaudhari & Vaidya, 1988). However, ASPEN guidelines 
recommend that the NST, a multidisciplinary team comprised of physicians, dietitians, 
pharmacists, and nurses who coordinate the provision of PN, should ensure that PN treatment 
meets the quality and safety guidelines (Mirtallo et al., 2004). Knowledgeable dietitians included 
on NSTs at NICUs can assist in the improvement of the nutritional statuses and growth rates of 
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neonate patients (Sneve, Kattelmann, Ren, & Stevens, 2008). This strategy is seen in many ICUs 
globally. Porcelli’s study (2004) indicates that five of eight NICUs in North Carolina employ 
experienced neonatal dietitians who assist decision support (Porcelli, 2004). However, in our 
study, when participants described the professionals involved in PN treatment, we discovered that 
dietitians rarely carry out nutritional decision-making in NICUs. Only one of the NICUs in our 
study had a dietitian who was deeply engaged in PN treatment.   
Similarly, an experienced pharmacist acting as a member of the NST is vital to ensure 
effective and safe PN treatment. Our study found that PN formulations were most often prepared 
by pharmacists; however, there was a small percentage of participants who indicated that the nurse 
staff compound the PN in their unit. These findings differ somewhat from Katoue et al.’s research 
(2016) which noted that in the studied NICUs in Kuwait, the pharmacist compounds PN 
formulations (Katoue et al., 2016).  However, our findings indicate that approximately 70% of the 
PN treatment was compounded by pharmacists and 20% by nurses. These results replicate the 
finding of Neves’s study (2014) which indicated that 76% of compounding was performed by 
pharmacy staff and 23% by nurse staff. (Neves, Pereira-Da-Silva, & Femandez-Llimos, 2014). 
According to ASPEN guidelines, the pharmacist must be the professional who prepares, labels, 
stores, dispenses, and distributes PN formulations (Mirtallo et al., 2004). Based on their 
knowledge and expertise, pharmacists can carry out a pharmaceutical review of PN formulations 
ensuring the appropriateness and compatibility of the PN elements (Boullata, 2012).    
In developed countries, it is more likely to observe NSTs providing PN treatment. Thus, 
studies performed by Sneve et al. (2008) and Traeger et al. (1986) noted significant positive 
outcomes in patients, such as higher growth rates and higher prescriptions of lipids, protein, 
calcium, phosphorous and sodium after implementing an NST. These teams are most often 
comprised of a physician, pharmacist, nurse, and dietitian in North American NICUs (Sneve et 
al., 2008; Traeger et al., 1986).  However, there are still some NICUs in developed countries that 
report the absence of NSTs in their units. This is the case in many Australian NICUs where a 
nationwide survey found that more than half of these units did not have an NST (Ali et al., 2006). 
In our study, most of the participants pointed out that PN treatment is provided by a group of 
health professionals from different backgrounds, such as physicians, pharmacists, and nurses; 
however, these teams are not formally recognized in their institutions as NSTs, and their duties 
were not exclusively related to providing nutrition support. As the respondents opined, the lack 
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of a recognized NST was likely primarily due to the shortage of financial and human resources in 
their institutions.  
Similarly, the lack of financial resources may account for the reason that only five of the 
sixteen participants noted that their units had a laminar flow hood designated for preparing PN 
treatment. Four of these five participants noted correctly that their NICU features a laminar flow 
hood. Of these five participants, the remaining participant asserted incorrectly that his NICU had 
a laminar flow hood while his colleagues, correctly, denied that their NICU had this device. 
Inconsistencies noted in this and other responses may result from health professionals lacking in-
depth participation in their respective NICUs’ PN practices.   
Similarly, Chaudhari and Vaidya (1988) found that the PN formulation in their NICUs 
was not conducted under a laminar flow hood (Chaudhari & Vaidya, 1988). Nevertheless, twenty 
years later, the same researcher reported that the sepsis rate decreased after the implementation of 
a laminar flow hood and training on aseptic procedures (Chaudhari, & Kadam, 2006).  
Recognizing potential opportunities for advancement is the first step in improving practices and 
outcomes. The Institute for Safe Medication Practices’ guidelines for safe preparation of 
compounded sterile preparations (CSP), including PN formulations, points out that a 
compounding area must have a laminar flow hood and that the preparing professional should not 
prepare multiple CSPs concurrently (Institute for Safe Medication Practices, 2016).  
Our study indicated that seven out of sixteen interviewees follow protocols or consensus 
developed by their units or by the Ecuadorian Ministry of Health. Six out of sixteen participants 
referred to published guidelines, which differs from Katoue et al.’s findings. This study found that 
six out of seven pharmacists used protocols developed by their NICUs and, additionally, most 
also referred to ASPEN guidelines to manage PN treatment (Katoue et al., 2016). Similar to 
Katoue’s findings, Alli (2006) noted that three-quarters of their study’s participants said that their 
NICUs had a hospital protocol for PN management (Ali et al., 2006). ASPEN and the British 
Association of Perinatal Medicine suggest that the potential complications associated with PN 
treatment may be decreased by the use of PN guidelines and a regular audit process (Mirtallo et 
al., 2004; British Association of Perinatal Medicine, 2016).  When the interviewees were asked 
about potential errors during PN practices and measures they take to prevent PN-related risks, the 
majority of participants of one NICU mentioned that as a part of preventive measures, their units 
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perform regular audits of PN formulations. However, audit practices during other stages of the 
PN process were not described (e.g., ordering, labelling, storing, administering).  
In our study, the vast majority of professionals involved in PN treatment noted that they 
referred to either published guidelines, such as ESPGHAN, ASPEN, Asociacion Espanola de  
Pediatria, SIBEN, or unpublished guidelines, such as protocol or consensus for better PN 
practices. The use of these guidelines demonstrates our studies’ participants’ desire to provide a 
quality PN treatment; however, this may provide an opportunity for improvement for NCIUs to 
unify their practices and develop protocols based on published guidelines that meet the needs of 
their neonatal populations.  
Our study also found that the range of amino acids (1 to 4g/kg/day) prescribed to preterm 
and term neonates at the beginning of their PN treatment is within the range recommended by 
ESPGHAN guidelines; however, the minimum dose prescribed to infants was slightly lower than 
the 1.5 to 3-4g/kg/day proposed by these guidelines (Koletzko et al., 2005). Other guidelines, 
including ASPEN, the British Association of Perinatal Medicine, and the Nutritional Care of 
Preterm Infants’ guidelines, recommend higher minimum doses of amino acids at the beginning 
of PN treatment than the ESPGHAN guidelines.  (Mirtallo et al., 2004; British Association of 
Perinatal Medicine, 2016; Embleton & Simmer, 2014). Similarly, the range of lipids administered 
to preterm neonates by our study’s participants was within the ESPGHAN range for preterm 
neonates which proposes minimum values of 0.25g/kg/day; however, doses administered to term 
neonates during our study were considerably higher than the doses proposed in these guidelines 
(Koletzko et al., 2005). Conversely, the ASPEN and the British Association of Perinatal Medicine, 
and the Nutritional Care of Preterm Infants’ guidelines propose initiating PN with higher 
minimum values (2 to 3g//kg/day) of lipids for preterm and term infants (Mirtallo et al., 2004; 
British Association of Perinatal Medicine, 2016; Embleton & Simmer, 2014).  
The glucose infusion rate ranges reported by interviewees are within the range 
recommended by the ESPGHAN guideline (4 to 8mg/kg/min) (Koletzko et al., 2005). However, 
the British Association of Perinatal Medicine and the Practice of Parenteral Nutrition in VLBW 
and ELBW Infants propose ranges with higher maximum doses from 4 to 12mg/kg per minute 
(British Association of Perinatal Medicine, 2016; Embleton & Simmer, 2014). Our results reveal 
that study participants, for the most part, prescribe macronutrients, amino acids, glucose, and 
lipids according to published guidelines, most often the ESPGHAN guidelines.  
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Another finding of our study is that all of the NICUs developed an Excel conversion 
spreadsheet to help professionals automate entering and ordering PN solutions to avoid potential 
errors during the prescription of this treatment. Although the four NICUs are not using the same 
PN order form to prescribe PN and the information included in the Excel conversion spreadsheet 
varies, generally the ordering process at these NICUs could be considered standardized. Similarly, 
in their study Puangco, Nguyen, and Sheridan described the process of automating order entries 
and calculations in their institutions. Dietitians, pharmacists, and computer programmers 
developed PN software using tables and algorithms.  This software assists the prescriber by 
providing maximum defaults for electrolytes and maximum osmolarity for dextrose solutions 
based on the venous access site used to deliver PN treatment. From a separate calculation entry, 
the appropriate dextrose, amino acid, and lipid levels are provided (Puangco, Nguyen, & 
Sheridan,1997). In our study, participants, as noted previously, developed a conversion 
spreadsheet to calculate the appropriate maximum and minimum defaults for the PN ingredients 
to avoid catastrophic overdose complications.  
Evidently, NICUs develop automated order entry systems according to their PN 
formulations to improve the quality of treatment.  Lehmann, Conner, and Cox (2004) found that 
the development of an online PN order entry system at the NICU in Johns Hopkins Hospital 
allowed the NICU to decrease calculation errors and osmolarity beyond the range during the 
ordering process (Lehmann, Conner, & Cox, 2004). However, there are some NICUs at which the 
prescription process is still handwritten. Katoue et al. (2016) found that there were issues, 
including legibility and missing or inadequate ingredient amounts, on handwritten order forms at 
NCIUs where automated ordering was not implemented (Katoue et al., 2016).   
Finally, through this survey, our study found that the vast majority of interviewees 
reported performing a biochemistry assessment before initiating PN treatment in a patient. The 
most frequently performed test assessed the patient’s electrolytes, blood glucose level, and CBC. 
In patients undergoing PN treatment, the fluid balance and blood glucose level were assessed 
approximately every 12 hours; but nevertheless, our respondents reported a disparity in the range 
and frequency of assessments within these parameters. The British Association of Perinatal 
Medicine recommends regular monitoring of patients receiving PN. These guidelines propose a 
weekly anthropometric assessment which measures the infant’s length and head circumference, 
and daily measurement of the patient's weight during the first week of life. Similarly, during the 
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first week of a neonate's life, the fluid balance, electrolytes, proteins, and bilirubin tests must be 
performed daily, and blood glucose level monitoring must be performed every six or eight hours 
(British Association of Perinatal Medicine, 2016).  
Statistically, VLBW, ELBW, and preterm neonates can die or suffer severe life-long 
consequences, including poor health and early mortality, if they do not receive adequate 
nutritional treatment. PN practice literature in the developing world, including Ecuador, is notably 
inferior to that of developed countries. For this reason, our findings provide insight into PN 
management in a country that has not been previously described in the literature. Understanding 
the experience of NICUs in countries that lack resources for providing PN has the potential to 
help improve these NICUs’ PN practices. Our Ecuadorian study’s results have the potential to 
help improve PN practices in other developing countries that face circumstances similar to those 
in Ecuador. Globally, NICUs in developing countries may find our research relevant to their 
situations which may allow them to deliver better PN care.  
  
3.5.1 Limitations  
Due to the study’s limited timeframe and logistical challenges, the questionnaire was not 
validated for question validity. This limitation may result in the exclusion of some questions that 
were not adequately discussed and questions that were out of the range of some participants duties.   
  Our study’s considerable quantity of data was challenging to manage. This is an established 
limitation of the grounded theory method and a limitation of our study.  
  
3.5.2 Recommendations  
Our study found previously unknown information which allowed us to understand and 
formulate a theory about practices in the four NICUs in Quito. It was gratifying to discover that 
most of the professionals deeply involved in the prescription of PN base their practice on 
published or unpublished guidelines; however, there are still opportunities for quality 
improvement. As described in the discussion section, regular auditing of PN practices should be 
a mandatory part of the PN program to identify and correct deficiencies. In addition, the creation 
of an NST which exclusively provides nutritional support and the development of protocols or 
consensus that translates into unified criteria has the potential to help professionals from different 
backgrounds better serve their neonate populations.  
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 Furthermore, the implementation of a laminar flow hood will help the PN compounding 
process meet the published safety recommendations. Also, as was mentioned in the discussion 
section, the ordering process could be considered standardized at the studied four NICUs. 
However, regular inter-hospital meetings between NICU professionals with the aim of sharing 
experiences and resources will further help these NICUs standardize the entire PN process. This 
unified practice between the NICUs could allow hospitals to make considerable quality and safety 
improvements. Further in-depth research on the PN compounding process is needed to allow 
researchers to better understand how pharmacists and nurses manage this important step of the 
PN treatment.  
3.6 Conclusion  
The PN practices in the four NICUs in Quito were not previously documented in the 
literature. Through this study, we discovered that the PN practices in these units are similar to 
many of the practices described in studies on PN practices in NICUs in developing countries. Our 
study shows that NICUs in Quito similarly refer to guidelines or protocols; therefore, the ranges 
of amino acids, lipids, and glucose infusion rates are within the ranges proposed by recognized 
guidelines. Nevertheless, our study found that there are opportunities for safety and quality 
improvement. Awareness of these opportunities will allow NICUs to fill gaps in their procedures 
to ensure better practices and, therefore, safer PN treatment. The absence of an official NST in 
some of the NICUs is one such opportunity for improvement. Furthermore, only half of the NICUs 
have developed a PN protocol or consensus to assist them in providing PN treatment. Finally, this 
survey found that a small percentage of NICUs have a laminar airflow hood in the compounding 
area for PN formulation.  
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4. PRESENCE OF COMPLICATIONS RELATED TO PARENTERAL NUTRITION 
TREATMENT IN NEONATE PATIENTS RECEIVING THIS TREATMENT: A 
RETROSPECTIVE CHART REVIEW 
4.1 Objective:  
Examine the prevalence of the most common complications associated with PN in patients 
who received PN   
4.2 Methods:  
4.2.1 Methodology  
The inpatient medical records of infants undergoing PN treatment, from June 1, 2016, to 
June 30, 2017, were reviewed. Neonate patients were selected as they are one of the main patient 
populations who receive parenteral nutrition treatment. This retrospective medical record review 
was conducted to determine the prevalence of hypoglycemia, hyperglycemia, PN-associated 
cholestasis (PNAC), and central line-associated bloodstream infections (CLABSI) in neonatal 
patients undergoing PN treatment. In assessing the credibility of the interview findings, this 
retrospective medical record review and PN guidelines allowed us to corroborate them.  
Patient medical records from HGDC and HGEG were not reviewed because they were not 
provided by their respective NICUs.  Meanwhile, the medical records department and NICUs at 
HGOIA and HGONA provided the official records of patients who received PN treatment, paper 
health records, and an appropriate place to review these records. Through their representatives at 
the “Eugenio Espejo Hospital of Specialities Ethics Committee,” the Ecuadorian Ministry of 
Health Ethics Committee approved this project for all participating hospitals:  HGONA, HGOIA, 
HGDC, and HGEG. All hospitals involved in this project agreed to contribute to the improvement 
of PN practices in their institutions and agreed to participate in this study. In addition, the 
University of Saskatchewan Ethics Committee approved this research project.   
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4.2.2 Sample  
In order to obtain the research population, inclusion and exclusion criteria were applied to 
the medical records of neonates who received PN treatment. For the power calculation of the 
sample size, a ninety-five percent level of confidence and a five percent margin of error were 
proposed.  Finally, 98 and 104 medical records of neonate inpatients admitted to the HGONA and  
HGOIA’s NICUs from June 1, 2016, to June 30, 2017, inclusive, who were less than 28-days-old 
and had received one round PN treatment for more than three consecutive days were randomly 
selected from a list in excel.   
4.2.3 Inclusion criteria  
All the medical records of neonate patients who had received one round of PN treatment 
from June 2016 to June 2017, who were less than 28-days-old, and who had received more than 
three consecutive days of PN treatment were included in the population.   
4.2.4 Exclusion criteria  
Infant patients with congenital hepatic or biliary disorders, major cardiac anomalies, or 
other congenital or acquired disorders associated with hepatic disease, who were more than 
28days-old, who had received less than three days of PN treatment, or more than one round of PN 
treatment were excluded from the population.  
4.2.5 Analytic Methods  
The prevalence of hyperglycemia, hypoglycemia, and PNAC in neonate patients at 
HGONA and HGOIA was determined by examining the laboratory reports and biochemical tests. 
Based on the AAP cut-offs, hypoglycemia was defined as serum concentrations of glucose less 
than 45mg/dL (2.5mmol/L) and hyperglycemia as serum concentrations of glucose over 
150mg/dL (8.3mmol/L) ) or over 125mg/dL (6.9 mmol/L) in blood glucose concentrations in one 
or more occasions (Adamkin, D. ,2011; Hwang, Newman, Philla, & Flanigan, 2018).  In this 
study, the prevalence of PNAC in neonate patients was defined as a conjugated bilirubin ≥ 1mg/dL 
(17.1 umol/L) as the AAP considers abnormal conjugated bilirubin as a conjugated bilirubin 
concentration over 1mg/dL (17.1umol/L) when the total bilirubin (TB) is at or below 5mg/dL 
(85umol/L) or over 20% of the TB when the TB is higher than 5mg/dL (Maisels et al., 2004). 
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Although the term direct bilirubin and conjugated bilirubin are not synonymous, the term 
conjugated bilirubin is used in this study.  
The Centers for Disease Control and Prevention (CDC) defines CLABSI as “a primary 
bloodstream infection (BSI) in a patient that had a central line within the 48-hour period before 
the development of the BSI and is not due to an infection at another site…The CLABSI 
surveillance definition overestimates the true incidence of CRBSI” (O'Grady et al., 2011, p 20). 
The National Center for Biotechnology Information outlines that the evaluation of CLABSI 
requires a blood culture for organisms that are not commonly present on the skin, and two or more 
blood cultures for organisms that are commonly present on the skin (Haddadin & Regunat, 2018). 
The etiology of CLABSI involves organisms such as gram-positive bacteria (coagulase-negative 
Staphylococci, enterococci, and Staphylococcus aureus) gram-negative bacteria (Klebsiella, 
Enterobacter, Pseudomonas, E. Coli, Acinetobacter) Candida, and others (Atilla, Doğanay, Kefeli  
Çelik, Demirağ, & Kiliç, 2017; Haddadin & Regunat, 2018). In this study, CLABSI was 
determined by the presence of a positive blood culture reporting growth of any of the previously 
described pathogens in patients receiving PN treatment.   
4.2.6 Statistical Analysis  
Biochemical results and microbiologic data were presented as a frequency with its 
respective percentages and averages, standard deviation, minimum and maximum values. Chi-
square and independent t-tests were performed to test for significant differences between the two 
hospitals. All statistical analyses were performed using IBM SPSS Statistics 25 for Windows 
Server 2012 R2.  
4.3 Results  
4.3.1 Medical records review results   
4.3.1.1 Demographic characteristic of the patients on PN  
  From June 2016 to June 2017, 279 neonate patients received PN at HGONA and 235 at 
HGOIA. To determine which patients met the inclusion and exclusion criteria, all medical records 
of neonate patients who received PN treatment were reviewed at both hospitals. At HGONA, 128 
patients met the criteria, and 142 patients met the criteria at HGOIA. At HGONA, the sample size 
consisted of 98 records, and the sample size at HGOIA consisted of 104 records. The gender 
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distribution in the HGONA records was 57 male patients (58%) and 41 female patients (42%). In 
the HGOIA records, there were 47 male patients (45%) and 57 female patients  
(55%). A Chi-square test of goodness-of-fit was performed to determine whether there is a 
statistical difference between gender populations in both hospitals. The gender population was 
equally distributed between both hospitals, p=0.065 (Table 4.1).   
  
Table 4.1 Gender distribution in HGONA and HGOIA  
  
Gender  HGONA  
n (%)  
HGOIA  
n (%)  
Male 
Female  
57 (58)  
41 (42)  
47 (45)  
57 (55)  
  
  
The mean weight when initiating PN treatment at HGONA was 1832 (SD 628.5) grams, 
while at HGOIA the mean weight was 1637 (SD 628.3) grams. The weight of patients at the 
beginning of PN treatment at HGONA was statistically higher compared to the weight of patients 
at HGOIA, p=0.029. Similarly, birth length was statistically higher at HGONA, 42cm (SD 4.0) 
compared to the patients’ length at HGOIA, 40cm (SD 4.3), p=0.010. Although the weight of 
neonates upon completion of their PN treatment was not statistically different between both 
NICUs, p=0.202, weight gain was higher for HGOIA’s patients: 149 grams compared to 68 grams 
of weight gain in HGONA’s neonates. Gestational age was measured by the Capurro method. 
Birth weight did not differ significantly between the hospitals, p=0.112 (Table 4.2).   
  
Table 4.2 Neonate population’s gestational age, weight, and length  
Variable  HGONA   HGOIA   
  Mean (min-max)  SD  Mean (min-max)  SD  
Gestational age (weeks)  34.1 (28-42)  2.7  34.0 (28.3-40)  2.5  
Birth weight (g)  1906 (815-4190)  640.6  1759 (640-3570)  665.1  
Weight begin PN (g)*  1832 (815-4460)  628.5  1637 (580-3310)  628.3  
Weight finish PN (g)  1900 (755-4305)  622.2  1786 (540-3445)  635.6  
Birth length (cm) *  42 (34-53)  4.0  40 (30-49)  4.3  
SD= standard deviation, min= minimum value, max= maximum value   
PN= parenteral nutrition  
*p < 0.05  
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The mean age of neonates at the beginning of PN treatment at HGONA was 2.5 (SD 3.9) 
days, while at the HGOIA the mean age at the beginning of treatment was 3.7 (SD 3.2) days. The 
age of patients at the beginning of PN treatment at HGONA was statistically lower compared to 
the age of patients at HGOIA, p=0.024. Similarly, the age of patients upon completion of their 
PN treatment was statistically lower at HGONA, 12.6 (SD 6.9) days compared to the patients’ 
age at HGOIA, 15.7 (SD 8.3), p=0.005. Additionally, the mean birth weight recovery in HGONA 
patients was statistically lower, 11 (SD 5.7) days compared to the birth weight recovery in HGOIA 
patients, 15 (SD 7.5) days, p=0.0006. The duration of PN treatment and hospitalization length did 
not differ significantly in the populations at the hospitals, p=0.351 (Table 4.3).   
  
Table 4.3 Neonate population’s age, duration, birth weight recovery regard to PN treatment  
Variable  HGONA   HGOIA   
  Mean (min-max)  SD  Mean (min-max)  SD  
Age begin PN* (days)  2.5 (0-27)  3.9  3.7 (0-23)  3.2  
Age finish PN* (days)  12.6 (3-37)  6.9  15.7 (4-50)  8.3  
Duration of PN (days)  10 (3-29)  6.4  11.9 (3-46)  8.4  
Birth weight recovery* (days)  11 (0-27)  5.7  15 (1-43)  7.5  
Hospitalization length (days)  27 (8-75)  14.2  29 (6-99)  17.2  
SD= standard deviation, min= minimum value, max= maximum value, PN= parenteral 
nutrition *p < 0.05  
  
The regimen of PN treatment at HGONA was 86% individual formulation and 14% 
standard and individual formulations. Conversely, at HGOIA  100% of the PN treatment was 
individual formulations. A Chi-square test of goodness-of-fit was performed to determine whether 
there is a statistical difference between the regimens of PN formulation at the hospitals. The 
regimen of PN formulation provided to the patients was not equally distributed p= 0.0001 (Table 
4.4).  Similarly, there were statistical differences between the two NICUs regarding the reasons 
for ceasing PN treatment. Thus, at HGONA 84% of patients’ PN treatment ceased due to an 
increase of enteral feeds and 16% due to other reasons. On the other hand, 67% of HGOIA’s 
patients ceased PN treatment due to increased enteral feeds and 33% because of other reasons 
p=0.013 (Table 4.5). Reasons to begin PN and venous access site were equally distributed in both 
hospitals, p=0.473 (Table 4.6 and Table 4.7).   
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Table 4.4 Regimen of PN formulation  
Variable  HGONA  
  
 HGOIA   
Regimen*  individual  standard/ 
individual  
individual  standard  
  86%  14%  100%  0%  
                       *p < 0.05  
 
 
Table 4.5 Reasons to cease PN treatment  
Variable  HGONA  
  
 HGOIA   
Reasons to cease PN*  Increase of enteral 
feeds  
Others  Increase of enteral 
feeds  
Others  
  84%  16%  67%  33%  
PN= parenteral nutrition        
*p < 0.05  
  
Table 4.6 Reasons to begin PN treatment  
Variable  HGONA  
  
HGOIA   
Reasons to begin PN  <1.5kg  Others  <1.5kg  Others  
  24%  76%  28%  72%  
PN= parenteral nutrition        
  
   
Table 4.7 Venous access site  
Variable  HGONA  
  
HGOIA  
Venous access site  PICC  Others  PICC  Others  
  95%  5%  93%  7%  
                      PICC= peripherally inserted central catheter  
  
The majority of patients used a PICC line as the venous access site to receive PN treatment 
in both NICUs. A very low percentage of patients received PN treatment through other venous 
access sites, including a central line and umbilical line followed by a central line, an umbilical 
line followed by a PICC line and an umbilical line exclusively.  
Among other reasons to begin PN, 49% and 33% of patients presenting diagnoses of 
respiratory distress syndrome who were connected to mechanical ventilation received PN 
treatment at HGONA and HGOIA respectively. Furthermore, other reasons, such as necrotizing 
enterocolitis and digestive intolerance, are shown in Table 4.8.  
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Table 4.8 Reason to begin PN 
Reasons to begin PN  HGONA  
n (%)  
HGOIA  
n (%)  
<1500g  23 (24)  29 (28)  
Caloric protein malnutrition  1 (1)  3 (3)  
Digestive intolerance  4 (4)  2 (2)  
GI malformations  3 (3)  14 (13)  
Necrotizing enteritis  5 (5)  4 (4)  
Pneumothorax  1 (1)  3 (3)  
Respiratory distress syndrome  48 (49)  34 (33)  
Risk of necrotizing enteritis  3 (3)  4 (4)  
Post-surgical myelomeningocele  0 (0)  1 (1)  
NPO  10 (10)  10 (9)  
                                   NPO= nil per os (nothing by mouth)  
                                               GI= gastrointestinal   
  
Among the other reasons to stop PN treatment, patient records listed catheter infiltration, 
hyperbilirubinemia, hyperglycemia, septic shock, erythematous zone related the PICC access site, 
etc. The distribution of the reasons to cease PN is shown in Table 4.9.  
Table 4.9 Reasons to cease PN  
Reasons to cease PN  HGONA  
n (%)  
HGOIA  
n (%)  
Catheter infection suspicion  1 (1)  0 (0)  
Catheter infiltration  1 (1)  3 (3)  
Cholestasis  1 (1)  5 (5)  
Hyperbilirubinemia  2 (2)  1 (1)  
Increase of enteral feeds  82 (84)  70 (67)  
Septic Shock  2 (2)  3 (3)  
Hyperglycemia  4 (4)  2 (2)  
Arm edema related to the PICC area  1 (1)  2 (2)  
Death  0 (0)  7 (6%)  
Hemodynamic decompensation  0 (0)  1 (1)  
Coagulopathy  0 (0)  1 (1)  
Erythematous zone related to the PICC area  2 (2)  1 (1)  
Low volume to deliver  0 (0)  1 (1)  
Surgery  0 (0)  1 (1)  
Catheter afunctional  0 (0)  1 (1)  
N/R  2 (2)  5 (5)  
                         PICC= peripheral inserted central catheter             N/R= not reported  
As previously described, the reasons to cease PN treatment were significantly different at 
the hospitals’ NICUs. At HGONA and HGOIA respectively, 84% and 67% of patients stopped 
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treatment due to an increase of enteral feed. Therefore, HGOIA showed a significantly higher 
percentage of patients who ceased PN for other reasons (33% versus 16%).  In order to obtain a 
reason that might account for this difference, the birth weight and medical conditions of patients 
who stopped PN for other reasons were reviewed.    
Even though the birth weight cut-offs, below 1.5kg and over 1.5kg, were equally 
distributed in both NICUs (p=0.328 and p=0.986 respectively), a higher percentage of neonates 
(17.1%) who stopped PN at HGOIA were ELBW compared to 7.1% of neonates at HGONA. Due 
to the small values, a Chi-square test of goodness-of-fit was not appropriate to determine whether 
there is a statistical difference between ELBW infants at both NICUs (Table 4.10).  
Table 4.10 Birth weight of patients who were ceased PN for other reasons  
  HGONA 
n (%)  
HGOIA 
n (%)  
<1000g  1 (7.1)  5 (17.1)  
<1500g  5 (35.6)  13 (44.6)  
>1500g  9 (64.2)  16 (55.1)  
     
  
Similarly, the medical conditions of patients who ceased PN for other reasons were 
reviewed. There were four cases of gastrointestinal malformations (GI) (13.8%) in HGOIA 
patients compared to zero cases in HGONA’s patients. Two cases of pneumothorax (6.9%) were 
described in HGOIA’s patients, and zero cases were noted at HGONA. The distribution of medical 
conditions is shown in Table 4.11.  
  
Table 4.11 Medical conditions of patients who were ceased PN for other reasons  
Medical conditions  HGONA 
n (%)  
HGOIA 
n (%)  
VLBW  4 (28.5)  8 (27.5)  
Risk of necrotizing enteritis  1 (7.1)  2 (6.9)  
Necrotizing enteritis  0  1 (3.4)  
GI malformation  0  4 (13.8)  
Pneumothorax  0  2 (6.9)  
Respiratory distress syndrome  7 (50)  7 (24.1)  
                    VLBW= very low birth weight         GI= gastrointestinal  
As is shown in Table 4.10 and 4.11, ELBW cases and other medical conditions may 
account for the differences in the two NICU’s other reasons to stop PN.  
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4.3.1.2 Prescribed Macronutrients  
The mean amino-acid dose prescribed when initiating PN treatment at HGONA was 2.6 
(SD 0.4) g/kg per day while at the HGOIA the mean dose was 2.9 (SD 0.4) g/kg per day. The 
amino-acid dose at the beginning of PN treatment at HGONA was statistically lower compared 
to the amino-acid dose used at HGOIA, p=0.0001. Similarly, the D-glucose infusion rate used at 
the beginning of PN treatment was statistically lower at HGONA, 5.2 (SD 0.8) mg/kg per minute 
compared to the rate used at HGOIA, 7.5 (SD 1.6), p=0.0001. Additionally, the lipid dose used at 
HGONA was statistically higher, 2.1(SD 0.6) g/kg per day compared to the dose used in HGOIA’s 
patients, which was 1.5 (SD 0.5) g/kg per day, p=0.0001. Finally, energy intake was significantly 
higher at HGONA, 102.1 (SD 24.3) kcal/kg per day compared to the intake of HGOIA’s patients, 
which was 91.7 (SD 34.6) kcal/kg/day, p=0.019. The D-glucose dose used to begin PN treatment 
was not significantly different at the two studied hospitals, p=0.684 (Table 4.12).   
  
Table 4.12 Prescribed Macronutrients  
Prescribed Macronutrient  HGONA   HGOIA   
  Mean (min-max)  SD  Mean (min-max)  SD  
Amino-acid (g/kg/day) *  2.6 (1.2-3.6)  0.4  2.9 (1.7-3.8)  0.4  
D-glucose (g/kg/day)  10.6 (3.3-29)  4.3  10.8 (5.6-17)  2.4  
D-glucose infusion rate 
(mg/kg/min) *  
5.2 (2.8-7.2)  0.8  7.5 (3.8-12)  1.6  
Lipid (g/kg/day) *  2.1 (0.4-3.3)  0.6  1.5 (0.2-2.8)  0.5  
Energy intake (kcal/kg/day) *  102.1 (52-150)  24.3  91.7 (18-182)  34.6  
         * p < 0.05  
  
4.3.1.3 Complications associated with PN treatment  
Conjugated bilirubin (CB) levels over or equal to 1 mg/dL (17.1umol/L) at patients’ 
baselines were equally distributed in HGONA’s and HGOIA’s NICUs, p=0.638; however, during 
week one to week four of PN treatment, these hospitals reported statistical differences (p=0.002, 
p=0.020, p=0.0001, and p=0.005 respectively). HGONA presented more cases of PNAC during 
the first four weeks of treatment than HGOIA. Conversely, plasma glucose levels below 45mg/dL 
were not significantly different at the hospitals as these levels were responsible for 1% of the cases 
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reported at HGONA compared to 6% at HGOIA, p=0.069. Furthermore, blood glucose levels over 
150mg/dL were not statistically remarkable, p=0.171 (12% at HGONA versus 7% at HGOIA).  
Finally, the presence of positive blood cultures was noted in 1% of cases at HGONA’s NICU and 
8% of cases at HGOIA’s NICU or 1.0 cases per 1000-line days and 6.4 cases per 1000- line days 
respectively. Due to the small number of cases observed, a Chi-square test of goodness-of-fit was 
not appropriate to determine whether there is a statistical difference between the NICUs (Table 
4.13).  
Table 4.13 Complications associated with PN treatment  
Test and Culture   HGONA   HGOIA  Combined data  
  YES  NO  Not 
reported  
YES  NO  Not 
reported  
Total 
cases  
%  
Mean 
%  
CB baseline ≥ 1mg/dL (17.1umol/L)   16%  81%  3%  14%  86%  0%  30  15  
CB week 1 ≥ 1mg/dL (17.1umol/L) *  35%  54%  11%  18%  80%  2%  53  26.5  
CB week 2 ≥ 1mg/dL (17.1umol/L) *  29%  39%  32%  19%  60%  21%  48  24  
CB week 3 ≥ 1mg/dL (17.1umol/L) *  14%  12%  74%  9%  45%  46%  23  11.5  
CB week 4 ≥ 1mg/dL (17.1umol/L) *  6%  4%  90%  5%  26%  69%  11  5.5  
CB week 1 to 4 (combined data)              33.7  16.8  
Blood glucose <45mg/dL (2.5mmol/L)  1%  96%  3%  6%  93%  1%  7  3.5  
Blood glucose >150mg/dL 
(8.3mmol/L)  
12%  86%  2%  7%  92%  1%  19  9.5  
Positive Blood culture  1%  0%  99%  8%  0%  92%  9  4.5  
        CB= direct bilirubin   TB= total bilirubin         *p <0.05   
 
4.4 Discussion  
  As previously described in the Methods section of this study, patients’ medical records at 
HGDC and HGEG were not assessed because an official record of patients undergoing PN 
treatment was not provided by their NICUs. For this reason, only HGOIA’s and HGONA’s 
patients’ medical records were reviewed to examine the presence of complications associated with 
PN treatment. Based on the interviews, the researchers noted that HGOIA’s NICU has a laminar 
flow hood to prepare PN while HGONA’s NICU does not. HGONA’s NICU reported having a 
dietitian as a part of the NICU team that provides PN treatment. Furthermore, from official 
records, it was reported that HGONA has 40 and HGOIA has 55 neonatal beds. The number of 
neonates receiving PN annually was 257 and 216 respectively. Although there is no great 
difference in the number of neonatal beds and patients receiving PN treatment at these two 
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hospitals, there may be value in comparing these NICUs to evaluate potential benefits or 
drawbacks of involving a nutritionist and laminar flow hood in PN treatment.  
  Our study found that the reasons to stop PN were statistically different at HGONA and 
HGOIA's NICUs; at HGONA, the vast majority of neonates ceased PN because they reached full 
enteral feeds while in HGOIA's NICU, approximately one-third of patients stopped PN due to 
other reasons, including complications or even death.  These other reasons were present in both 
NICUs; however, in HGONA's patients, these other reasons constituted the reason to cease PN in 
a significantly lower percentage of cases. The literature describes that early initiation of enteral 
feeding could reduce the time required to reach full enteral feeds and decrease the number of days 
on PN treatment thereby reducing the side effects associated with prolonged use of PN (Kuzma-
O'Reilly et al., 2003).  In our study, both NICUs reported using milk banks and following the 
protocol of beginning early trophic enteral feeding in patients on PN. Enteral feeding of patients 
receiving PN nutrition was not recorded in our study, which is an apparent limitation of this study. 
This enteral feeding information may help us explain why there is a statistical difference in the 
reasons to cease PN at the two studied institutions. Other health conditions, however, may account 
for the discrepancy in reasons to stop PN.   
 The age of neonates at the beginning of PN was significantly younger at HGONA 
compared to HGOIA. In their study, Kuzma-O'Reilly et al. found that after the implementation of 
improved practices, the mean day to start PN in VLBW patients was 1.81± 0.88 days; additionally, 
this study found an earlier initiation of PN resulted in reaching enteral nutrition earlier (Kuzma-
O'Reilly et al., 2003). The early age of infants at the beginning of PN treatment may account for 
the reason that HGONA has a higher percentage of patients who stop PN due to reaching full 
enteral feed. Even though ESPGHAN guidelines note that the initiation of PN should depend on 
the individual circumstances of the patient, age, and weight, the British Association of Perinatal 
Medicine and ESPGHAN guidelines recommend that PN treatment in newborn infants should be 
commenced shortly after birth. The British Association of Perinatal Medicine notes that glucose 
and amino acids must be initiated soon after birth and lipids within 24 hours of birth (British 
Association of Perinatal Medicine, 2016; Koletzko et al., 2005).  
 However, there could be other reasons that explain the difference in the number of cases 
of patients that stopped PN for other reasons at HGOIA. Even though birth weights showed no 
significant difference between both NICUs, the weight at the beginning of PN treatment and the 
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birth length were significantly lower in HGOIA' patients.  Additional exploration of the birth 
weight and the medical conditions of patients who stopped PN for other reasons at the two NICUs 
was performed. There were no significant differences in birth weights at the lower cut off, 1500 
grams and over 1500 grams; however, a Chi-square test of goodness-of-fit to determine whether 
there was a statistical difference between ELBW infants at HGONA’s and HGOIA’s NICUs was 
not possible due to the very low number of cases (one and five respectively). Similarly, the cited 
medical conditions were not comparable due to the presence of so few cases; however, HGOIA' 
patients presented cases of necrotizing enteritis, GI malformations, and pneumothorax, but 
HGONA's patients did not.  Medical conditions and the extremely low birth weight of the patients 
at HGOIA may account for the other reasons to cease PN treatment.  
 Our study found that the mean amino acids, glucose infusion rate, and energy intake 
prescribed were significantly higher at HOGIA's NICU compared to HGONA’s NICU; 
nevertheless, the mean lipid prescription was higher at HGONA's NICU compared to HGOIA's 
NICU. According to ASPEN, ESPGHAN, British Association of Perinatal Medicine, Practice of 
Parenteral Nutrition in VLBW and ELBW Infants, and the Neonatology/Paediatrics-Guidelines 
on Parenteral Nutrition, the range of amino acids doses and the GIR prescribed by HGOIA's 
NICUs are within the recommended range. However, the minimum dose of amino acids and GIR 
prescribed by HGONA are slightly lower than the dose recommended in these guidelines. The 
maximum prescribed dose was within the recommended range. The energy intake provided by 
both NICUs was beyond the minimum recommended intake. This might be explained by the fact 
that patients who were receiving partial PN; their enteral nutrition were not recorded in this study.  
The lipids prescribed by both NICUs were within the appropriate range recommendations, but 
our study found that HGONA’s patients were prescribed significantly more lipids than patients at 
HGOIA. Lipids are the source of essential fatty acids, linoleic acid, and alpha-linolenic acids. 
During the data collection, we observed that HGOIA's NICU prescribed 20% intravenous lipids 
and soybean oil, olive oil, medium-chain triglycerides, and fish oil (SMOF) lipids. When 
personnel prescribe SMOF lipids, there is an additional order form which specifies the use of this 
type of fat, but its use is limited to very few patients.  
  On the other hand, HGONA's PN order form did not specify the use of SMOF lipids; 
however, a professional deeply involved in PN treatment noted that this unit prescribes SMOF 
lipids to a small number of patients as well. The British Association of Perinatal Medicine notes 
   
67  
  
that, based on the available evidence, the benefits and potential hazards of these new lipids are 
still unclear (British Association of Perinatal Medicine, 2016). Further studies on the outcomes of 
patients on PN solutions that contain SMOF lipids are needed.  
 Finally, our study found that there was no significant difference between the two NICUs 
regarding the prevalence of blood glucose levels over 150mg/dL (8.3mmol/L) or below 45mg/dL 
(2.5mmol/L) which can diagnose hyperglycemia and hypoglycemia. The average hyperglycemia 
prevalence (9.5%) found in the combined data from HGONA’s and HOGIA’s NICUs is lower 
than the prevalence of hyperglycemia (57%) found in a retrospective chart review study of 93 
ELBW infants admitted to Texas Children’s Hospital, Houston, USA from January 1, 2001 to 
December 31, 2001. This study aimed to determine the prevalence of hyperglycemia, defined as 
at least one value above 150mg/dL during the first week of life, in ELBW neonates undergoing 
PN treatment (Hays, Smith, & Sunehag, 2006).   
  Another retrospective chart review study of 169 ELBW neonates admitted to University 
Hospital, San Antonio, Texas, from January 1998 to December 2001, found an 88% incidence of 
hyperglycemia (defined as a plasma glucose level ≥150mg/dL) in ELBW infants receiving PN 
treatment during the first two weeks of life in a predominantly Hispanic population (Blanco, 
Baillargeon, Morrison, & Gong, 2006). Conversely, Kao’s retrospective observational study 
(2006) of 201 ELBW infants undergoing PN treatment at two centers in Houston, Texas, from 
March 2000 to November 2003, aimed to determine the association between hyperglycemia, 
mortality, and infections. This study found a lower incidence (28%) of mild hyperglycemia (as 
serum glucose level 120-179mg/dL), and a 7% incidence of severe hyperglycemia (≥180mg/dL) 
(Kao, 2006).   
 Our results appear lower when compared to previous studies. This may be primarily 
because the neonate patients included in this study were patients of different birth weights not 
only ELBW infants which the previous studies used as their target groups. Thus, in our study, the 
mean weight at which PN was initiated was 1832g (815- 4460) and 1637g (580-3310) at HGONA 
and HGOIA respectively. From reviewing the pertinent literature, it is evident that in preterm 
infants limited insulin secretion capacity, activation of the hepatic glucose production, 
intermittent hypoxia, and other forms of stress lead to hyperglycemia (Rozance, & Hay 2010).  
Other potential reasons for this low prevalence may include  the low GIR values used by HGONA 
and HGOIA (mean of 5.2mg/kg/min [2.8- 7.2] and 7.5mg/kg/min [3.8-12] respectively) compared 
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to the guidelines’ recommended ranges (4-8, 4-12, or 7-12mg/kg/min) (Koletzko, Goulet Hunt, 
Krohn, & Shamir, 2005; British Association of Perinatal Medicine, 2016; Embleton & Simmer, 
2014). Finally, other potential reason might be a misreporting of hyperglycemia in patients 
undergoing PN treatment.   
  Our study found a prevalence of hypoglycemia (3.5%) lower than the incidence found in a 
Scottish randomized control trial in 29 neonates below 2000g undergoing three PN formulations 
during the first 48 hours of life: glucose, 2 in 1, and 3 in 1 formulations (55%, 90%, and 25% 
respectively). In this study, hypoglycemia was defined as a plasma glucose level < 46mg/dL 
(2.55mmol/L) (Murdock, Crighton, Nelson, & Forsyth, 1995). Similarly, an observational study 
in ten patients less than two weeks of age requiring cycled long-term PN admitted to Boston  
Children’s Hospital and Brigham and Women’s Hospital, Boston, USA, reported an incidence of 
hypoglycemia (glucose concentration <40mg/dL using reagent strip and capillary samples) of 
1.15% of all collected glucose concentrations and a 20% of incidence of hypoglycemia in neonate 
patients (Collier, Crouch, Hendricks, & Caballero, 1994).   
 As was previously noted in the discussion of the prevalence of hyperglycemia, including 
neonate patients in the same data set as infants of all gestational ages and birth weights may 
explain the low prevalence of hypoglycemia in our study. Lubchenco and Bard (1971) reported a 
higher (67%) incidence of hypoglycemia (glucose level <30mg/dL) in the preterm small 
gestational age (SGA) group compared to the term SGA (25%) and the post-term SGA (18%) 
groups in a randomized study of 374 infants over a 2-year period at Colorado Medical Center. 
Furthermore, this study showed a lower incidence of hypoglycemia in the large for gestational 
age (LGA) group when compared to the preterm LGA (37%), term LGA (4%), and post-term 
LGA (7%) groups (Lubchenco, & Bard, 1971). The incidences reported in Lubchenco’s study 
may account for the low prevalence of hypoglycemia found in our study. Finally, other potential 
reason might be a misreporting of hyperglycemia in patients undergoing PN treatment.  
 Due to the small number of cases where a positive blood culture was observed, a Chi 
square test of goodness-of-fit was not an appropriate method of determining whether there is a 
statistical difference between the NICUs in our study. The average prevalence of CLABSI 
observed in the combined data of HGONA’s and HGOIA’s NICUs was 4.5% or 4.06 cases per 
1000-line days. This prevalence is slightly higher compared to the prevalence found in Patrick et 
al.’s study (2013) of newborns admitted from January 1, 2008, to December 31, 2010 (1.7% or 
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18 CLABSI cases per 1000 patients). In this study, Patrick aimed to confirm the reliability of 
hospital records compared with CLABSI confirmed by sepsis control system (Patrick et al., 2013).  
Another study in North Carolina’s NICUs, which aimed to reduce CLABSI rates, reported a 
reduction of 71% from 3.9 infections per 1000-line days to 1.6 infections per 1000-line days 
(Fisher et al., 2013).    
  With a similar objective of reducing the incidence of CLABSI cases, a prospective study 
from January 2012 to September 2013 in Greece’s NICUs found a pre-intervention incidence rate 
of 12 cases per 1000-line days; however, after a quality intervention was implemented, the 
incidence decreased to 3.4 cases per 1000-line days (Rallis, Karagianni, Papakotoula, Nikolaidis, 
& Tsakalidis, 2016).   
   Conversely, when compared to previous results, our study demonstrated a statistical 
difference between our hospitals’ rates of PNAC in patients receiving PN treatment from week 
one to week four. HGONA’s NICU presented more cases of PNAC than HGOIA’s NICU in the 
four weeks of the treatment. Our study found the mean prevalence of PNAC (16.8%) in both 
NICUs from week one to week four of PN treatment was lower than the incidence (24%) of PNAC 
(as two consecutive tests of conjugated bilirubin > 2mg/dL) found in Javid et al.’s study (2011). 
Javid et al.’s study was a retrospective review of 176 surgical infants undergoing PN treatment 
admitted from 2001 to 2006 at Seattle’s NICU. This study also found that prematurity was 
significantly associated with the development of cholestasis (Javid et al., 2011).   
  Furthermore, Christensen, Henry, Wiedmeier, Burnett, & Lambert (2007), in their historic 
cohort study of 9861 neonates admitted from 2002 to 2006 to Utah’s NICUs, found that the 
incidence of PNAC (as direct bilirubin >2mg/dL) is significantly correlated with the duration of 
PN treatment. This study found an incidence of 14%, 43%, 72% and 85% of PNAC in neonates 
receiving PN treatment for 14 to 28 days, 29 to 56 days, 52 to 100 days, and over 100 days 
respectively (Christensen, Henry, Wiedmeier, Burnett, & Lambert, 2007). Finally, Repa’s double-
blind randomized study (2018) of 230 ELBW neonates receiving PN treatment admitted from 
2012 to 2015 at Austria’s NICUs, aimed to evaluate if a mixed lipid emulsion decreases the 
incidence of PNAC (as conjugated bilirubin >1.5mg/dL or 25umol/L) in ELBW infants. This 
study reported an incidence of 10.1% in the intervention group and 15.9% in the control group 
(Repa, 2018). The prevalence of PNAC found in our study is slightly higher compared to the 
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incidence found in Christensen’s study; however, our findings are consistent with the incidence 
observed in the control group in Repa’s study.   
   It is crucial to note that the potential complications presented in this study are only 
correlated with PN treatment. We are not attributing the causation of these complications to PN 
treatment. To identify the cause and effect relationship between PN treatment and these potential 
complications, further research in these NICUs is required.  
  Other possible causes of hyperglycemia, hypoglycemia, and PNAC will be discussed.  
According to the AAP, hypoglycemia is commonly observed in infants who are small for their 
gestational age, late-preterm infants, and those who are born to diabetic mothers (Adamkin, 2011). 
Similarly, the APP notes that hyperglycemia is frequently observed in ELBW neonates and is 
most commonly caused by postnatal corticosteroid therapy, stress caused by surgery, respiratory 
distress syndrome, and sepsis (Hwang et al., 2018).  Finally, PNAC in infants can be caused, not 
only by PN treatment, but by obstructive and hepatocellular factors. The most common medical 
conditions included in these categories are extrahepatic biliary atresia and idiopathic neonatal 
hepatitis (Harb, & Thomas, 2007).   
4.4.1 Limitations  
  Since the medical records we examined were physical and mostly handwritten, revision, 
interpretation, and potentially missed or omitted information were indeed limitations of this study.  
 An additional limitation of this study was our inability to review the other two NICU’s 
documents due to the absence of records of patients who received PN treatment. This review 
would have allowed us to better understand their practices. Reviewing the medical records of all 
hospitals in our study would have provided a more comprehensive research base.  
  The time to first full enteral feeding and the amount of nutrition provided were not recorded 
in our study. This information may have allowed us to explain some of our results, such as birth 
weight recovery and reasons to cease PN treatment. This unrecorded information is another 
limitation of our study.   
4.4.2 Recommendations  
  As noted in the discussion section, this project only studied the association of potential 
complications (hyperglycemia, hypoglycemia, PNAC, and CLABSI) with PN treatment. For 
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quality and safety improvement in the participating NICUs, further research on the direct 
relationship between PN and these complications is strongly recommended.  
  A regular audit of PN treatment in the NICUs is also recommended by our study. Regular 
auditing in NICUs that aim to provide safe PN treatment and better outcomes for their patients is 
a strongly endorsed practice.   
  Even though the CLABSI rates in this study are slightly higher compared to the rates 
reported in NICUs in developed countries and the PNAC prevalence is consistent with the 
prevalence found in developed countries, it is strongly recommended that hospitals develop a 
protocol of regular surveillance and clinical diagnosis of these and other complications associated 
with PN therapy.  
  The discussion section also indicated that a limitation of this study was that the time to first 
enteral feeding and the amount of this feeding were not recorded; further studies should research, 
not only PN treatment, but also enteral nutrition as this may better account for some growth 
outcomes in patients receiving both treatments.  
  Further observational study of these NICUs’ PN practices is recommended. Observations, 
in combination with our interviews and medical record reviews, will allow for a broader 
understanding of the PN practices in these units. The digitalization of the medical records may 
bring better and more flexible management of patient information. This digitalization might also 
be an excellent tool to increase the speed and efficiency of the PN auditing process.  
4.5 Conclusion  
 Reviewing the patients’ medical records and PN guidelines allowed us to assess the 
credibility of our theory and obtain a better understanding of the PN practices in the public NICUs 
in Quito; however, as described in the recommendations, observations of the PN practices in the 
NICUs would expand this theory.  Our study found that there were statistical differences between 
NICUs in several of the measured variables. Among these findings, were that PN was initiated 
significantly earlier and that there was a higher percentage of patients who ceased PN treatment 
because they reached full enteral feeds in HGONA's patients.  Regarding the range of amino acids, 
lipids, and glucose prescribed, there is consistency with the guidelines’ recommendations and the 
interviewees’ responses; however, there are a few prescribed minimum doses that exceeded the 
recommended range. Finally, there were no significant differences observed regarding the 
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potential complications associated with PN treatment, except for the prevalence of PNAC which 
was significantly higher in HGONA’s NICU compared to HGOIA’s NICU.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
73  
  
REFERENCES 
  
Adamkin, D. (2011). Postnatal glucose homeostasis in late-preterm and term infants. Pediatrics,                 
            127(3), 575-9.   
Adamkin, D., & Radmacher, P. (2014). Current trends and future challenges in neonatal               
            parenteral nutrition. Journal of Neonatal-perinatal Medicine, 7(3), 157-64.  
Ahmed, M., Irwin, S., & Tuthill, D. (2004). Education and evidence are needed to improve 
neonatal parenteral nutrition practice. Journal of Parenteral and Enteral Nutrition, 28,  
176-179. doi:10.1177/0148607104028003176  
Ainsworth, S., Furness, J., & Fenton, A. (2001). Randomized comparative trial between 
percutaneous longlines and peripheral cannulae in the delivery of neonatal parenteral 
nutrition. Acta Pædiatrica, 90(9), 1016-1020.  
Ainsworth, S., & Mcguire, W. (2015). Percutaneous central venous catheters versus peripheral 
cannulae for delivery of parenteral nutrition in neonates. Cochrane Database Of 
Systematic Reviews, 2015(10), CD004219.  
Al-Rafay,S., & Al-Sharkawy, S. (2012). Educational Outcomes Associated with providing a 
Comprehensive Guidelines Program about nursing care of preterm neonates receiving  
Total Parenteral Nutrition. Clinical Nursing Research, 12 (2), 142-158  
Ali, A. B., Chapman-Kiddell, C., & Reeves, M. M. (2007). Current practices in the delivery of 
parenteral nutrition in Australia. European Journal of Clinical Nutrition, 61, 554-560. 
doi:http://dx.doi.org/10.1038/sj.ejcn.1602547  
Atilla, A., Doğanay, Z., Kefeli Çelik, H., Demirağ, M., & S Kiliç, S. (2017). Central 
lineassociated blood stream infections: Characteristics and risk factors for mortality over 
a 5.5-year period. Turkish Journal of Medical Sciences, 47(2), 646-652.  
Ayers, P., Adams, S., Boullata, J., Gervasio, J., Holcombe, B., Kraft, M., . . . Worthington, P. 
(2014). A.S.P.E.N. Parenteral Nutrition Safety Consensus Recommendations. Journal of 
Parenteral and Enteral Nutrition, 38(3), 296-333.  
Barría, Lorca, & Muñoz. (2007). Randomized Controlled Trial of Vascular Access in Newborns 
in the Neonatal Intensive Care Unit. Journal of Obstetric, Gynecologic & Neonatal 
Nursing, 36(5), 450-456.  
Berlana, D., Barraquer, A., Sabin, P., Chicharro, L., Pérez, A., Puiggrós, C., . . . 
MartínezCutillas, J. (2014). Impact of parenteral nutrition standardization on costs and 
quality in adult patients TT  - Impacto de la estandarización de la nutrición parenteral en 
costes y calidad en pacientes. Nutrición Hospitalaria, 30, 351-358.  
doi:10.3305/nh.2014.30.2.7575  
Blanco, C., Baillargeon, J., Morrison, R., & Gong, A. (2006). Hyperglycemia in extremely low 
birth weight infants in a predominantly Hispanic population and related morbidities. 
Journal of Perinatology, 26(12), 737-73741.  
Boitano, Bojak, Mccloskey, Mccaul, & Mcdonough. (2010). Improving the safety and 
effectiveness of parenteral nutrition: Results of a quality improvement collaboration. 
Nutrition in Clinical Practice : Official Publication of the American Society for 
Parenteral and Enteral Nutrition, 25(6), 663-71.  
Bolisetty, S., Osborn, D., Sinn, J., & Lui, K. (2014). Standardised neonatal parenteral nutrition 
formulations – an Australasian group consensus 2012. BMC Pediatrics, 14, 48. 
doi:10.1186/1471-2431-14-48  
   
74  
  
Boullata, J. I. (2012). Overview of the Parenteral Nutrition Use Process. Journal of Parenteral 
and Enteral Nutrition, 36, 10S-13S. doi:10.1177/0148607111433624  
Boullata, J. I., Gilbert, K., Sacks, G., Labossiere, R. J., Crill, C., Goday, P.,…American Society 
for Parenteral and Enteral Nutrition (2014). A.S.P.E.N Clinical Guidelines: Parenteral 
nutrition ordering, order review, compounding, labeling, and dispensing. Journal of 
Parenteral and Enteral Nutrition, 38 (3), 334-377.  
Bryan, H., Wei, Hamilton, R., Chance, & Swyer. (1973). Supplemental intravenous alimentation               
            in low-birth-weight infants. The Journal of Pediatrics, 82(6), 940-944.  
British Association of Perinatal Medicine. (2016). The provision of parenteral nutrition within 
neonatal services : A framework for practice. Retrieved from  
http://www.bapm.org/publications/documents/guidelines/Parenteral Nutrition April 
2016.pdf  
Buonocore, G., Bracci, Rodolfo. editor, Weindling, Michael. editor, & SpringerLink. (2018).  
Neonatology : A Practical Approach to Neonatal Diseases (2nd ed. 2018.. ed.).  
Burjonrappa, S. C., & Miller, M. (2012). Role of trace elements in parenteral nutrition support of 
the surgical neonate. Journal of Pediatric Surgery, 47, 760-771.  
doi:10.1016/j.jpedsurg.2012.01.015  
Chuah, S. W., Ng, D.H., Liu, P., Liu, H., Ng, J.L., & Ling, K.L. (2013). The use of Parenteral 
Nutrition in an Acute Care Hospital. Annals of the Academy of Medicine, Singapore, 42  
(8), 395-400  
Chaudhari, S., & Kadam, S. (2006). Total Parenteral Nutrition in Neonates. Indian Pediatrics,  
    953–964.  
Chaudhari, S., & Vaidya, U. (1988). Total Parenteral Nutrition in India. Indian Pediatrics, 935–      
            940.  
Chowdhary, S.K., Chitnis, M., Chowdhary, S., Gossen, F., & Lazarus,C. (2000). Pediatric    
             Parenteral Nutrition: South African Model and its Relevance to the Developing  
             Countries. Indian Pediatrics, 37, 187-189  
Christensen,R., Henry, E., Wiedmeier, S., Burnett, J., &  Lambert, D. (2007). Identifying   
             patients, on the first day of life, at high-risk of developing parenteral nutrition- 
             associated liver disease. Journal of Perinatology, 27(5), 284-28490.  
Cohen, M. (2012). Safe Practices for Compounding of Parenteral Nutrition. Journal of Parenteral  
            and Enteral Nutrition, 36(2_suppl), 14S-19S.  
Collier, S., Crouch, J., Hendricks, K., & Caballero, B. (1994). Use of Cyclic Parenteral Nutrition   
            in Infants Less Than 6 Months of Age. Nutrition in Clinical Practice, 9(2), 65-68.  
Creswell, John W. (2006). Qualitative Inquiry and Research Design: Choosing among Five 
Approaches  (Second ed).  
Curtis, C. (2018). Technology in Parenteral Nutrition Compounding. Nutrition in Clinical  
Practice : Official Publication of the American Society for Parenteral and Enteral 
Nutrition, Nutrition in clinical practice : official publication of the American Society for 
Parenteral and Enteral Nutrition, 17 April 2018.  
Dudrick, S. J., Macfadyen Jr, B. V., Van Buren, C. T., Ruberg, R. L., & Maynard, A. T. (1972). 
Parenteral hyperalimentation: Metabolic problems and solutions. Annals of surgery, 
176(3), 259.   
   
75  
  
Duggan, Rizzo, Cooper, Klavon, Fuchs, Gura, . . . Lo. (2002). Effectiveness of a clinical 
practice guideline for parenteral nutrition: A 5‐year follow‐up study in a pediatric 
teaching hospital. Journal of Parenteral and Enteral Nutrition, 26(6), 377-381.  
Dutta, S., Singh, B., Chessell, L., Wilson, J., Janes, M., McDonald, K.,… Fusch, C. (2015). 
Guidelines for feeding very low birth weight infants. Nutrients, 7, 423-442.  
doi:10.3390/nu7014023  
Dweck, H., Brans, Y., Sumners, J., & Cassady, G. (1976). Glucose Intolerance in Infants of Very 
Low Birth Weight. Neonatology, 30(1-4), 261-267.  
Eleni-Dit-Trolli, S., Kermorvant-Duchemin, Huon, Mokthari, Husseini, Brunet, . . . Lapillonne. 
(2009). Early individualised parenteral nutrition for preterm infants. Archives of Disease 
in Childhood - Fetal and Neonatal Edition, 94(2), F152-3.  
Embleton, N. D.,& Simmer, K. (2014). Practice of Parenteral Nutrition in VLBW and ELBW 
Infants. Nutritional Care of Preterm Infants: Scientific Basis and Practical Guidelines, 
110, 177-189. doi:10.1159/000358466  
Embleton, N. E., Pang, N., & Cooke, R. J. (2001). Postnatal Malnutrition and Growth Retardation: 
An Inevitable Consequence of Current Recommendations in Preterm  
Infants? Pediatrics, 107, 270-273. doi:10.1542/peds.107.2.270  
Fisher, D., Cochran, K., Provost, L., Patterson, J., Bristol, T., Metzguer, K., . . . McCaffrey, M. 
(2013). Reducing central line-associated bloodstream infections in North Carolina 
NICUs. Pediatrics, 132(6), E1664-E1671.  
Fusch, C., Bauer, K., Bohles, H.J., Jochum, F., Koletzko, B., Krawinkel, M.,…Muhlebach, 
S.(2009). Neonatology/Paediatrics-Guidelines on Parenteral Nutrition, Chapter 13. GMS 
German Medical Science, 7, 1612-3174  
Garland, J., Alex, C., Sevallius, J., Murphy, D., Good, M., Volberding, A., . . . Maki, D. (2008). 
Cohort Study of the Pathogenesis and Molecular Epidemiology of Catheter‐Related 
Bloodstream Infection in Neonates With Peripherally Inserted Central Venous Catheters.  
Infection Control and Hospital Epidemiology, 29(3), 243-249.  
Grant, J. P. (1980). Handbook of total parenteral nutrition. Philadelphia: W. B. Saunders 
Company.  
Haddadin Y, Regunath H. Central Line Associated Blood Stream Infections (CLABSI) [Updated  
2018 Oct 27]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018  
Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430891/  
Harb, R., & Thomas, D. (2007). Conjugated hyperbilirubinemia: Screening and treatment in older 
infants and children. Pediatrics in Review, 28(3), 83-91.  
Hays, S., Smith, E., & Sunehag, A. (2006). Hyperglycemia is a risk factor for early death and 
morbidity in extremely low birth-weight infants. Pediatrics, 118(5), 1811-1818.  
Heimler, R., Bamberger, J., & Sasidharan, M. (2010). The Effects of Early Parenteral Amino 
Acids on Sick Premature Infants. The Indian Journal of Pediatrics, 77(12), 1395-1399.  
Hill, L. (2015). Nutrition support practices in South African ICUs: Results from a nationwide pilot 
survey. 31(2), 42-50.  
Hudson, L. M., & Boullata, J. I. (2014). A Quality Improvement Case Report. Journal of  
             Parenteral and Enteral Nutrition, 38, 378-384. doi:10.1177/0148607113518802 
Hwang, M., Newman, R., Philla, K., & Flanigan, E. (2018). Use of Insulin Glargine in the  
Management of Neonatal Hyperglycemia in an ELBW Infant. Pediatrics, 141, S399.  
Institute for Safe Medication Practices. (2017). ISMP's list of high-alert medication.  
   
76  
  
http://www.ismp.org/Tools/highalertmedications.pdf.   
Institute for Safe Medication Practices. (2016). ISMP Guidelines for the safe preparation of 
compounded steril preparations. Hospital Pharmacy, 48(4), 282-294.   
Javid, Malone, Dick, Hsu, Sunseri, Healey, & Horslen. (2011). A contemporary analysis of 
parenteral nutrition–associated liver disease in surgical infants. Journal of Pediatric 
Surgery, 46(10), 1913-1917.  
Kamala, F., Boo, N., Cheah, F., & Birinder, K. (2002). Randomized controlled trial of heparin 
for prevention of blockage of peripherally inserted central catheters in neonates. Acta 
Pædiatrica, 91(12), 1350-1356.  
Kao,L., Morris, B., Lally, K., Stewart, C., Huseby, V., & Kennedy, K. (2006). Hyperglycemia 
and morbidity and mortality in extremely low birth weight infants. Journal of 
Perinatology, 26(12), 730-736.  
Katoue, M.G., Al-Taweel, D., Matar, K.M., & Kombian, S.B. (2016). Parenteral nutrition in 
hospital pharmacies Exploring the practices and identifying opportunities for quality 
improvement. International Journal of Health Care Quality Assurance, 29(6), 664-674  
Khashu, M., Harrison, A., Lalari, V., Lavoie, J., & Chessex, P. (2009). Impact of shielding 
parenteral nutrition from light on routine monitoring of blood glucose and triglyceride 
levels in preterm neonates. Archives of Disease in Childhood - Fetal and Neonatal 
Edition, 94(2), F111-5.  
Klein, Ravenis, Kusenda, & Scavo. (2010). Parenteral Nutrition–Associated Conjugated 
Hyperbilirubinemia in Hospitalized Infants. Journal of the American Dietetic 
Association, 110(11), 1684-1695.  
Köglmeier, J., Day, C., & Puntis, J. (2008). Clinical outcome in patients from a single region 
who were dependent on parenteral nutrition for 28 days or more. Archives of Disease in 
Childhood, 93(4), 300-302.  
Koletzko, B., Goulet, O., Hunt, J., Krohn, K., & Shamir, R. (2005). 1. Guidelines on Paediatric  
            Parenteral Nutrition of the European Society of Paediatric Gastroenterology, Hepatology  
            and Nutrition (ESPGHAN) and the European Society for Clinical Nutrition and  
            Metabolism (ESPEN), Supported by the European Society of Paedia. Journal of  
            Pediatric Gastroenterology and Nutrition, 41(Supplement 2), S1–S4.  
            https://doi.org/10.1097/01.mpg.0000181841.07090.f4  
Kumpf, V. (2006). Parenteral Nutrition‐Associated Liver Disease in Adult and Pediatric Patients.  
            Nutrition in Clinical Practice, 21(3), 279-290.  
Kuzma-O'Reilly, B., Duenas, M. L., Greecher, C., Kimberlin, L., Miller, D., Walker, D. J., . . . 
Greecher, C. (2003). Evaluation, Development and Implementation of Potentially Better 
Practices in Neonatal Intensive Care Nutrition. Pediatrics, 111, e461.  
doi:10.1542/peds.111.4.SE1.461  
Lang, T. (2005). Food control or food democracy? re-engaging nutrition with society and the                    
            environment. Public Health Nutrition, 8(6), 730-7. doi:     
            http://dx.doi.org.cyber.usask.ca/10.1079/PHN2005772  
Laborie, S., Denis, A., Dassieu, G., Bedu, A., Tourneux, P., Pinquier, D., . . . Claris, O. (2015).              
           Shielding Parenteral Nutrition Solutions From Light. Journal of Parenteral and Enteral              
           Nutrition, 39(6), 729-737.   
   
77  
  
Lapillonne, A., Fellous, L., Mokthari, M., & Kermorvant-Duchemin, E. (2009). Parenteral    
nutrition objectives for very low birth weight infants: results of a national survey. Journal 
of pediatric gastroenterology and nutrition, 48(5), 618-626.  
Lauriti, G., Zani, A., Aufieri, R., Cananzi, M., Chiesa, P., Eaton, S., & Pierro, A. (2014).    
           Incidence, Prevention, and Treatment of Parenteral Nutrition–Associated Cholestasis and   
           Intestinal Failure–Associated Liver Disease in Infants and Children. Journal of Parenteral              
           and Enteral Nutrition, 38(1), 70-85.  
Lavoie, J., Belanger, S., Spalinger, M., & Chessex, P. (1997). Admixture of a multivitamin                 
           preparation to parenteral nutrition: The major contributor to in vitro generation of              
           peroxides. Pediatrics, 99(3), E61-E65.  
Lehmann, C., Conner, K., & Cox, J. (2004). Preventing provider errors: Online total parenteral               
           nutrition calculator. Pediatrics, 113(4), 748-53.   
Lowe, J., Erickson, S., Schrader, R., & Duncan, A. (2012). Comparison of the Bayley II Mental                         
           Developmental Index and the Bayley III cognitive scale: Are we measuring the same              
           thing? Acta Paediatrica, 101(2), E55-E58.  
Lubchenco, L., & Bard, H. (1971). Incidence of hypoglycemia in newborn infants classified by              
            birth weight and gestational age. Pediatrics, 47(5), 831-8.  
MacKay, M., Anderson, C., Boehme, S., Cash, J., & Zobell, J. (2016). Frequency and Severity of 
Parenteral Nutrition Medication Errors at a Large Childrens Hospital After  
Implementation of Electronic Ordering and Compounding. Nutrition in Clinical Practice, 
31, 195-206. doi:10.1177/0884533615591606  
Maisels, M., Baltz, R., Bhutani, V., Newman, T., Palmer, H., Rosenfeld, W., . . . Weinblatt, H. 
(2004). Management of hyperbilirubinemia in the newborn infant 35 or more weeks of 
gestation. Pediatrics, 114(1), 297-316.  
McElhiney, L. (2009). An overview of United States pharmacopeia chapter 795 and american 
society of health-system pharmacists guidelines for nonsterile compounding.  
International Journal of Pharmaceutical Compounding, 13(6), 525-30.  
Miller, Malki, Vaidya, Ruben, Rastogi, Deepa, Bhutada, Alok, & Rastogi, Shantanu. (2014). 
From parenteral to enteral nutrition: A nutrition-based approach for evaluating postnatal 
growth failure in preterm infants. JPEN. Journal of Parenteral and Enteral Nutrition, 
38(4), 489-97.  
Mirtallo, J., Canada, T., Johnson, D., Kumpf, V., Petersen, C., Sacks, G., . . . Guenter, P. (2004). 
Safe Practices for Parenteral Nutrition. Journal of Parenteral and Enteral Nutrition, 28, 
S39-S70. doi:10.1177/0148607104028006S39  
Morgan, J., Bombell, S., & Mcguire, W. (1997). Early trophic feeding versus enteral fasting for 
very preterm or very low birth weight infants. Cochrane Neonatal Group, 2013(4), 
CD000504.  
Morgan, J., Young, L., & Mcguire, W. (2011). Delayed introduction of progressive enteral feeds 
to prevent necrotising enterocolitis in very low birth weight infants. Cochrane Database 
Of Systematic Reviews, 3(3), CD001970.  
Murdock, N., Crighton, A., Nelson, L., & Forsyth, J. (1995). Low birthweight infants and total 
parenteral nutrition immediately after birth. II. Randomised study of biochemical 
tolerance of intravenous glucose, amino acids, and lipid. Archives of Disease in 
Childhood, 73(1), F8-F12.  
   
78  
  
Nardo, P., Dupertuis, Y. M., Jetzer, J., Kossovsky, M. P., Darmon, P., & Pichard, C. (2008). 
Clinical relevance of parenteral nutrition prescription and administration in 200 
hospitalized patients: a quality control study. Clinical nutrition, 27(6), 858-864.   
Neves, A., Pereira-Da-Silva, L., & Femandez-Llimos, F. (2014). Prácticas de Preparación de 
Nutrición Parenteral Neonatal en Portugal: Comparación con las recomendaciones 
españolas. Nutrición Hospitalaria, 29(6), 1372-1379.  
O'Grady, N., Alexander, M., Dellinger, E., Gerberding, J., Heard, S., Maki, D., . . . Weinstein, 
R. (2002). Guidelines for the prevention of intravascular catheter-related infections. 
Clinical Infectious Diseases, 35(11), 1281-1307.  
O'Grady, N., Alexander, M., Burns, L., Dellinger, E., Garland, J., Heard, S., . . . Wise, Robert A.  
(2011). Guidelines for the prevention of intravascular catheter-related infections. 
Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society 
of America, 52(9), E162-E193.  
Oliveira, C., Nasr, A., Brindle, M., & Wales, P. (2012). Ethanol Locks to Prevent 
CatheterRelated Bloodstream Infections in Parenteral Nutrition: A Meta-Analysis. 
Pediatrics, 129(2), 318-29.  
Olsen, Anne L, Reinholdt, Jes, Jensen, Anders Mørup, Andersen, Leif P, & Jensen, Elsebeth 
Tvenstrup. (2009). Nosocomial infection in a Danish Neonatal Intensive Care Unit: A 
prospective study. Acta Pædiatrica, 98(8), 1294-1299.  
Oxford Centre for Evidence Based Medicine-Levels of Evidence (March 2009). Available               
            online:  https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-              
            evidence-march-2009/   
Patrick, Stephen W., Davis, Matthew M., Sedman, Aileen B., Meddings, Jennifer A., Hieber,               
            Sue, Lee, Grace M., . . . Schumacher, Robert E. (2013). Accuracy of hospital               
            administrative data in reporting central line-associated bloodstream infections in               
            newborns. (Report). Pediatrics, 131(3), S75.  
Pedrón Giner, C., Cuervas-Mons Vendrell, M., Galera Martínez, R., Gómez López, L., Gomis 
Muñoz, P., Irastorza Terradillos, I., . . . Grupo de Estandarización de La Senpe, S. (2017).  
Pediatric parenteral nutrition: Clinical practice guidelines from the Spanish Society of  
Parenteral and Enteral Nutrition (SENPE), the Spanish Society of Pediatric 
Gastroenterology, Hepatology and Nutrition (SEGHNP) and the Spanish Society of 
Hospital Pharmacy (SEFH). Nutricion Hospitalaria, 34(3), 745-758.  
Pildes, Rosita, Forbes, Audrey E., O&Amp;Apos, Connor, Sheilah M., & Cornblath, Marvin. 
(1967). The incidence of neonatal hypoglycemia—a completed survey. The Journal of 
Pediatrics, 70(1), 76-80.  
Poindexter, B. (2014). Approaches to growth faltering. World Review of Nutrition and Dietetics, 
110, 228-38.  
Poindexter, Langer, Dusick, & Ehrenkranz. (2006). Early provision of parenteral amino acids in 
extremely low birth weight infants: Relation to growth and neurodevelopmental 
outcome. The Journal of Pediatrics, 148(3), 300-305.e1.  
Porcelli, P. (2004). A Survey of Neonatal Parenteral Nutrition Design Practices in North Carolina. 
Journal of Perinatology, 24, 137-142. doi:10.1038/sj.jp.7210991  
Puangco, Nguyen, & Sheridan. (1997). Computerized PN Ordering Optimizes Timely Nutrition 
Therapy in a Neonatal Intensive Care Unit. Journal of the American Dietetic 
Association, 97(3), 258-261.  
   
79  
  
Puligandla, Janvier, Flageole, Bouchard, Mok, & Laberge. (2004). The significance of 
intrauterine growth restriction is different from prematurity for the outcome of infants 
with gastroschisis. Journal of Pediatric Surgery, 39(8), 1200-1204.  
Rallis, Karagianni, Papakotoula, Nikolaidis, & Tsakalidis. (2016). Significant reduction of central 
line–associated bloodstream infection rates in a tertiary neonatal unit. AJIC:  
American Journal of Infection Control, 44(4), 485-487.  
Ramakrishnan, N., Shankar, B., Lakshmi Ranganathan, D., Bharadwaj, A., & Venkataraman, R. 
(2016). Parenteral nutrition support: Beyond gut feeling? Quality control study of 
parenteral nutrition practices in a Tertiary Care Hospital. Indian journal of critical care 
medicine: peer-reviewed, official publication of Indian Society of Critical Care 
Medicine, 20(1), 36.   
Repa, Binder, Thanhaeuser, Kreissl, Pablik, Huber-Dangl, . . . Haiden. (2018). A Mixed Lipid 
Emulsion for Prevention of Parenteral Nutrition Associated Cholestasis in Extremely 
Low Birth Weight Infants: A Randomized Clinical Trial. The Journal of Pediatrics, 194, 
87-93.e1.  
Rigo, J., Marlowe, M., Bonnot, D., Senterre, T., Lapillonne, A., Kermorvant-Duchemin, E., . . . 
Colomb, V. (2012). Benefits of a new pediatric triple-chamber bag for parenteral 
nutrition in preterm infants. Journal of Pediatric Gastroenterology and Nutrition, 54(2), 
210-7.  
Rozance, P. J., & Hay Jr., W. W. (2010). Neonatal hyperglycemia. NeoReviews, 11(11), 
E632E638.  
Russell, R. B., Green, N. S., Steiner, C. A., Meikle, S., Howse, J. L., Poschman, K., . . . Petrini,  
J. R. (2007). Cost of Hospitalization for Preterm and Low Birth Weight Infants in the  
United States. Pediatrics, 120, e1-e9. doi:10.1542/peds.2006-2386  
Saugstad, O. (2017). 50 Years Ago in The Journal of Pediatrics: The Incidence of Neonatal 
Hypoglycemia—A Completed Survey: The Incidence of Neonatal Hypoglycemia—A 
Completed Survey. The Journal of Pediatrics, 180(C), 73.  
Schanler, R. J., Shulman, R. J., & Prestridge, L. L. (1994). Parenteral nutrient needs of very low 
birth weight infants. The Journal of Pediatrics, 125, 961-968. 
doi:10.1016/S00223476(05)82016-5  
Sitges-Serra, A., Linares, J., Perez, J., Jaurrieta, E., & Lorente, L. (1985). A randomized trial on 
the effect of tubing changes on hub contamination and catheter sepsis during parenteral 
nutrition. Journal of Parenteral and Enteral Nutrition, 9(3), 322-325.   
Smyth, N., Neary, E., Power,S., Feehan, S., & Duggan, S. (2013). Assessing appropriateness of 
parenteral nutrion usage in an acute hospital. Nutrition in Clinical Practice, 28 (2), 
232236  
Sneve, J., Kattelmann, K., Ren, C., & Stevens, D. (2008). Implementation of a Multidisciplinary 
Team That Includes a Registered Dietitian in a Neonatal Intensive Care Unit Improved 
Nutrition Outcomes. Nutrition in Clinical Practice, 23(6), 630-634.  
Stephens, Bonnie E., Walden, Rachel V., Gargus, Regina A., Tucker, Richard, McKinley, 
Leslie, Mance, Martha, . . . Vohr, Betty R. (2009). First-week protein and energy intakes 
are associated with 18-month developmental outcomes in extremely low birth weight 
infants.(Report). Pediatrics, 123(5), 1337-43.  
Tagare, A., Walawalkar, M., & Vaidya,U. (2013). Aggressive Parenteral Nutrition in sick very 
low birth weight babies: A Randomized Controlled Trial. Indian Pediatrics, 50, 954-956  
   
80  
  
Tresoldi, A. T., Padoveze, M. C., Trabasso, P., Veiga, J. F. S., Marba, S. T. M., von  
Nowakonski, A., & Branchini, M. L. M. (2000). Enterobacter cloacae sepsis outbreak in 
a newborn unit caused by contaminated total parenteral nutrition solution. American 
journal of infection control, 28(3), 258-261.  
Traeger, S., Williams, G., Milliren, G., Young, D., Fisher, M., & Haug, M. (1986). Total 
Parenteral Nutrition by a Nutrition Support Team: Improved Quality of Care. Journal of 
Parenteral and Enteral Nutrition, 10(4), 408-412.  
Trivedi, A., & Sinn, J. (2013). Early versus late administration of amino acids in preterm infants 
receiving parenteral nutrition. Cochrane Neonatal Group, 2013(7), CD008771.  
Turpin, R. S., Canada, T., Rosenthal, V. D., Nitzki-George, D., Liu, F. X., Mercaldi, C. J., & 
Pontes-Arruda, A. (2012). Bloodstream infections associated with parenteral nutrition 
preparation methods in the United States: a retrospective, large database analysis. 
Journal of Parenteral and Enteral Nutrition, 36(2), 169-176.   
Uslu, S., Ozdemir, H., Comert, S., Bolat, F., & Nuhoglu. A. (2010). The effect of low-dose 
heparin on maintaining peripherally inserted percutaneous central venous catheters in 
neonates. Journal of Perinatology, 30(12), 794-9.  
Uthaya, S., & Modi, N. (2014). Practical preterm parenteral nutrition: Systematic literature 
review and recommendations for practice. Early Human Development, 90, 747-753. 
doi:10.1016/j.earlhumdev.2014.09.002  
Van Den Akker, C. H., Te Braake, F. W., Schierbeek, H. B., Van Goudoever, J. J., Wattimena, 
D., Voortman, G., & Vermes, A. (2006). Effects of early amino acid administration on 
leucine and glucose kinetics in premature infants. Pediatric Research, 59(5), 732-735.  
Wilson, D., Verklan, M. T. & K A Kennedy, K. A. (2007). Randomized trial of percutaneous 
central venous lines versus peripheral intravenous lines. Journal of Perinatology, 27(2), 
92-926.  
World Health Organization. Reproductive Health Research. (2003). Kangaroo mother care : A 
practical guide. Geneva: Department of Reproductive Health and Research, World 
Health Organization.  
 Wright K, Ernst KD, Gaylord M S, Dawson J P, & Burnette T M. (2003). Increased Incidence 
of Parenteral Nutrition-Associated Cholestasis with Aminosyn PF Compared to 
Trophamine. Journal of Perinatology, 23(6), 444-44450.  
Yeung, M., Smyth, J., Maheshwari, R., & Shah, S. (2003). Evaluation of standardized versus 
individualized total parenteral nutrition regime for neonates less than 33  weeks 
gestation. Journal of Paediatrics and Child Health, 39(8), 613-617.  
  
  
  
  
  
  
  
 
 
 
   
81  
  
Appendix A 
 
SURVEY 
I.  GENERAL INFORMATION  
Number of questionnaire                            Date                                        Name of Interviewer 
Hospital name             Total beds number        Neonatal beds number  
How many neonate’s patients are admitted yearly in this hospital?  
How many are VLBW neonate’s patients are admitted yearly in this hospital?  
Academic Degree      Role           Years of experience           Average Number of hours that you work at the hospital   
II.     DESCRIPTION OF THE NEONATOLOGY AREA  
1. How many beds/ incubators/ places of care does the neonatology area at this institution have?  
 Places of basic care (Definition: basic care)   
 Places of intermediate care (Definition: intermediate care) 
 Places of intensive care (Definition: intensive care)   
2. Does this hospital have a laminar flow hood to prepare TPN? If your answer is YES, please mention the number  
of laminar flow hoods at the hospital.  
 Yes                            No           How many?   
3. Have been any change in the past 5 years?   What?  
III.    DESCRIPTION OF THE PATIENT OF THE NEONATOLOGY AREA  
4. How many neonate’s patients are receiving TPN yearly in this hospital?   
5. How many are VLBW neonate’s patients are receiving TPN annually in this hospital?   
6. Which are the most frequent reasons to begin TPN?  
                                                                                                                                           Sex _____  
                                                                                                                      Gestational age _____  
                                                                                                                      VLBW (<1500g) _____                       
                                                                                         Intrauterine growth retardation _____ 
                                                                                                            Digestive intolerance _____  
                                                                                                    Restricted enteral output _____                                                                                                                            
                                                                                                                  GI malformations _____  
                                                                                                             Necrotizing enteritis _____  
                                                                                                                       Short intestine _____ 
                                                                                                     Malabsorption Syndrome ____                              
                                                                                                                            Chylous leak ____  
                                                                                                               Esophageal rupture ____                                                                                                                            
                                                                                                                      Other_____________ 
7. Have been any change in the past 5 years?      What?   
IV.   HEALTH CARE PERSONNEL  
8. Is there a parenteral nutrition team (multidisciplinary team of nutritional support) in this hospital?  
                                            Yes                                           No   
If your answer is Yes, please answer the following questions  
9. Mention which professionals are involved in this parenteral nutrition team and their role (Write the  
professional degree that they have)  
If your answer to question 8 is No, please answer the following questions  
  10.  Mention which professionals are involved in the administration of TPN and their role? (Write the 
 professional degree that they have)  
  11. Which are the barriers toward having a functional NSTS?   
12. Who is the health professional that prepares parenteral nutrition solutions?   
                                             Nurse   ___                                                 
                                         Dietitian  ___  
                                    Pharmacist  ___  
                               Other __________  
13. Have been any change in the past 5 years?    What?  
V. PARENTERAL NUTRITION DESIGN  
14. What is the method that you use to make the parenteral nutrition orders?  
                                 Paper orders___                                       
                          Electronic orders___  
15. Do you write this order manually or digital?  
16. Could you provide me with a copy of the form that you use order TPN? Yes /  No  
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17. Where is TPN prepared?  
                                 Operating theatre   ___                              
                                      Pharmacy area   ___  
                                        Nutrition area ____  
                                 Neonatology area   ___                                      
                                             Other_________  
18. Do you use any TPN calculation software (ABACUS, Baxter) or   automated compounding devices (ACDs) 
 to prepare TPN formulations?  
19. Do you pack TPN formulations in a single compartment bags or more?  
20. Could you provide me with a copy the label that you use for TPN bags?  
21. How many days does the TPN unit work? In the case, the TPN unit does not work some days which 
 method do you use to supply TPN those days?  
22. If you prepare TPN bags for those days when the TPN unit is not operating, please explain how do you 
 store them?  
23. Where is parenteral nutrition delivered?  
                                    Basic Unit Care ___                                           
                      Intermediate Unit Care ___                               
                             Intensive Unit Care ___  
24. Which kind of in-line filters do you use to deliver TPN? 
25. How long does last TPN and how do you proceed when you infuse lipids?   
26. Which are the potential errors in TPN practices (order, prepare, storage, labelling, and administration)  
That you found during your daily practice and which measures do you take to prevent PN-related risks? 
 Please mention the frequency. (Ex. Doble- checking/ triple-chequing on the data entry, gravimetric  
analysis, visual inspection of each PN bag, sterility testing of isolated rooms/isolators and PN bags)  
27. Are you using a publish clinic guide to manage the TPN?   
                                 Yes                                                    No  
28. If your answer to question 27 is YES, please mention which Clinic guide, protocol, or actual 
 recommendations you are using to manage the TPN?  
                                                                                               ESPGHAN & ESPEN   __         
                  A.S.P.E.N American Society for Parenteral and Enteral Nutrition __  
       British Association for Parenteral and Enteral Nutrition Working Party __  
                                                                     British Society of Gastroenterology __  
                               Australasian Society for Parenteral and Enteral Nutrition __  
                                                        American Gastroenterological Association __  
                                                                         Asociación Española de Pediatría __                                                         
                                                         Other ________________________________   
29. If your answer to question 27 is No, please mention which clinic guide or protocol are you using to  
manage the TPN   
30. Is this clinic guide or protocol based on one of the above?   What? 
31. Could you provide a copy of this clinic guide or protocol?   Yes/ No 
32. What kind of TPN regimen do you use frequently?  
                                                                                     Always Individualised TPN   __                                                  
                                                                                     Mostly Individualised TPN   __  
                                                        Both individualized and Standardised TPN    __      
                                                                                      Mostly Standardised TPN    __  
                                                                                     Always individualised TPN    __  
33. What is the method that you are using to estimate the energy requirement of the patient?  
                                                                            Direct calorimetry___   
                                                                         Indirect calorimetry___  
                                                                         Prediction formulas___   
34. If you selected prediction formulas, what is the formula you use to calculate the energy requirement of 
 the patient?  
35. What is the value of proteins that you use to begin TPN in patients?   
___________%=________ gr/kg/d in preterm neonates   
___________%=________ gr/kg/d in term neonates  
  36. How do you calculate the carbohydrates (D- glucose) intake in patients?  
___________%=________ gr/kg/d in preterm neonates   
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___________%=________ gr/kg/d in term neonates  
37.   Which type of lipid emulsion do you use?   
                                    LCT at 10% __                                    
                                    LCT at 20% __  
                                    LCT at 30% __  
                                  MCT at 50% __  
                                      What is the value of lipids that you use to begin TPN in patients?  
         ________ gr/kg/d in preterm neonates   
         ________ gr/kg/d in neonates  
38. Which vascular line do you use most frequently to deliver the TPN?  
  Always  Most  Sometimes  Never  
Peripheral line          
Central line          
Peripherally inserted central catheter          
Umbilical          
39. Have been any change in the past 5 years?   What?  
VI.   PATIENT MONITORING  
Before to begin TPN  
40. Do you assess biochemistry measures before beginning TPN in the patient?  
Yes                                                          No  
41.  If your answer is Yes, please tell us which biochemistry measures you assess most frequently before 
 Beginning TPN in the patient  
  Always  Most times  Sometimes  Never  
Hemogram          
Urea/creatinine          
Electrolytes          
Hepatic function test          
Blood glucose Level          
Total proteins/Albumin          
Vitamins and minerals status          
Cholesterol          
Triglycerides          
Others ________________          
 42. Do you assess anthropometric measures before beginning TPN in the patient?  
                   Yes                                             No 
43. If the answer is Yes, please point out which anthropometric measures you use most frequently  
  Always  Most times  Sometimes  Never  
Weight          
Length          
Cephalic perimeter          
Other          
Patient on TPN  
44. How frequently do you assess fluid balance, blood glucose levels?  
  At least one per day  Every 12 hours  Every 8 Hours  Other  
Fluid balance          
Blood glucose levels          
Temperature          
Heart rate          
Respiratory Frequency          
45. How frequently do you assess anthropometric parameters?  
   Once per day  Twice per week  Other  
Weight        
Length    
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46. Have been any change in the past 5 years? What?  
VII.  MANAGE OF COMPLICATIONS                                                                                          
47. Regards to some complications such as hyperglycemia, hypoglycemia, hyperbilirubinemia, cholestasis, and 
 sepsis, which lab test and symptoms do you use to define them? Or do you base the diagnosis of these 
 complications in any international classification (ex. ICD)?  
48.  If you observe possible complications of TPN, what do you do?  
49. Do you have a clinic guide protocol to manage complications of TPN? If your answer is Yes, what is this 
clinic guide or protocol?  
                   Yes              No                                 What?  
50. Could you provide a copy of this clinic guide or protocol?  
51. Have been any change in the past 5 years?  What?  
VIII.  CEASING TPN  
52. Who decides to cease TPN?  
53. What is the reason to cease TPN? (At least half of a patient’s requirements are met, as the patient 
commences on an oral diet or enteral feeds, referring medical team makes the decision)  
54. Do you have a protocol to cease TPN? If your answer is Yes, what is this clinic guide or protocol  
              Yes                    No                         What?  
55. Do you have a follow-up protocol for patients following the termination of PN? If your  
answer is Yes, what is this clinic guide or protocol?  
                                          Yes                     No                        What?  
56. If your answer is yes in questions 55 or 56 Could you provide a copy of this clinic guide or protocol?  
57.  Have been any change in the past 5 years?  What?  
58.  Did you face any difficulty, problem, or challenge during the period that you have been involved in TPN 
administration?  What?  
  
Figure A. 1  Survey of health professionals delivering PN treatment at four neonatal 
intensive care unit (NICU)s. 
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Appendix B 
  
 
 
   Figure B.1  Parenteral nutrition order form 
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Appendix C 
Raw data from the interviews 
 
Table C.1 Description of the neonatal units 
    Places of basic 
care  
Places of 
intermediate care  
Places of 
intensive care  
Total 
(n=16)  
Another places  
HGONA  
(n=5)  
8±2 (3)  
Do not know (2)  
20±5.29 (3)  
Do not know (2)  
17±3.6 (3)  
Do not know (2)  
5  0  
HGOIA (n=4)  24.37±29.03 (4)  33±14.14 (4)  12 (4)  4  Isolation area 2 places (2)  
HGDC (n=4)  0 (3)  
Do not know (1)  
7.67±1.15 (3)  
Do not know (1)  
6.67±1.15 (3)  
Do not know (1)  
4  0  
HGEG (n=3)  4 (3)  4(3)  5 (3)  3  Infectiology 8 places (2)  
Infectiology 6 places (1)  
  (n=16)  (n=16)  (n=16)  16    
  
Table C.2 Presence of laminar flow hood 
Laminar flow 
hood  
Yes  No  Do not know  Didn’t 
answer  
Total (n=16)  
HGONA (n=5)  0  4  1  0  5  
HGOIA (n=4)  4  0  0  0  4  
HGDC (n=4)   1  2  1  0  4  
HGEG (n=3)  0  2  1  0  3  
Total  31.25%  
(n=5)  
50%  
(n=8)  
18.75% 
(n=3)  
0  100% (16)  
 
Table C.3 Existence of nutritional support team 
Existence of 
NST  
Yes  No  Do not know  Didn’t answer  Total 
(n=16)  
HGONA (n=5)  2  2  1  0  5  
HGOIA (n=4)  1  3  0  0  4  
HGDC (n=4)  0  4  0  0  4  
HGEG (n=3)  0  3  0  0  3  
Total  18.8%  
(n=3)  
75%  
(n=12)  
6.3% (n=1)  0  16  
  
Table C.4 Parenteral nutrition compounding process 
 Place of PN 
compounding  
Pharmacy  
unit  
NICU  Operating 
theater  
TPN  
unit  
Do not 
know  
Total 
(n=16)  
HGONA (n=5)  1  0  0  1  3  5  
HGOIA (n=4)  0  4  0  0  0  4  
HGDC (n=4)  2  0  2  0  0  4  
HGEG (n=4)  0  3  0  0  0  3  
  18.8%  
(n=3)  
43.8%  
(n=7)  
12.5%  
(n=2)  
6.3% 
(n=1)  
18.8%  
(n=3)  
16  
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Table C.5 Parenteral nutrition calculation process 
Method of 
calculations  
Software in 
excel  
manually  Software/ 
manual  
Total 
(n=16)  
HGONA (n=5)  5  0  0  5  
HGOIA (n=4)  2  1  1  4  
HGDC (n=4)  4  0  0  4  
HGEG (n=3)  3  0  0  3  
  87.5% (n=14)  6.3% (n=1)  6.3% (n=1)  16  
  
Table C.6 Parenteral nutrition storing process 
Storing PN  Not stored  
(prepare daily)  
Kept in Refrigeration 
(standard TPN)  
Total (n=16)  
HGONA 
(n=5)  
2  3  5  
HGOIA (n=4)  4  0  4  
HGDC (n=4)   4  0  4  
HGEG (n=3)  3  0  3  
  81.3% (n=13)  18.8% (n=3)  16  
 
Table C.7 Regimen of parenteral nutrition 
Regimen of 
PN  
Always 
individual 
(n=16)  
Mostly 
individual  
Both individual 
& standard  
Mostly 
standard   
Always standard 
soon after 
birth(n=16)  
HGONA 
(n=5)  
5  0  0  0  4  
HGOIA (n=4)  4  0  0  0  0  
HGDC (n=4)  4  0  0  0  0  
HGEG (n=3)  3  0  0  0  0  
Total  100% (n=16)  0  0  0  25% (n=4)  
  
Table C.8 Published guideline to manage parenteral nutrition treatment 
Use of published 
guideline  
Yes  No  Do not 
know  
Total 
(n=16)  
HGONA (n=5)  1  3  1  5  
HGOIA (n=4)  4  0  0  4  
HGDC (n=4)  1  3  0  4  
HGEG (n=3)  0  3  0  3  
  37.5%  
(n=6)  
56.3%  
(n=9)  
6.3% 
(n=1)  
16  
 
Table C.9 Unpublished guideline to manage parenteral nutrition treatment 
Use of unpublished 
guideline  
Consensus or protocol of 
the neonatology area  
MSP  
protocol  
Protocol in 
process  
Do not 
know  
N/A  Total 
(n=16)  
HGONA (n=5)  2  0  0  2  1  5  
HGOIA (n=4)  0  0  0  0  4  4  
HGDC (n=4)  0  2  1  0  1  4  
HGEG (n=3)  3  0  0  0  0  3  
  31.3% (n=5)  12.5%  
(n=2)  
6.3% (n=1)  12.5%  
(n=2)  
37.5%  
(n=6)  
16  
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Table C.10 Professional that prepares parenteral nutrition formulations 
 
Professional who 
prepares PN  
Pharmacist  Nurse  Do not 
know  
Total 
(n=16)  
HGONA (n=5)  4  0  1  5  
HGOIA (n=4)  4  0  0  4  
HGDC (n=4)  3  0  1  4  
HGEG (n=3)  0  3  0  3  
  68.8% 
(n=11)  
18.8%  
(n=3)  
12.5%  
(n=2)  
16  
  
  
  
 
  
 
